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http://dx.doi.org/10.10heimer’s disease (AD), including incidence and prevalence, mortality rates, health expenditures
and costs of care, and effect on caregivers and society in general. It also explores the roles and unique
challenges of long-distance caregivers, as well as interventions that target those challenges. An
estimated 5.2 million Americans have AD. Approximately 200,000 people younger than 65 years
with AD comprise the younger onset AD population; 5 million comprise the older onset AD popu-
lation. Throughout the coming decades, the baby boom generation is projected to add about 10
million to the total number of people in the United States with AD. Today, someone in America
develops AD every 68 seconds. By 2050, one new case of AD is expected to develop every 33 sec-
onds, or nearly a million new cases per year, and the total estimated prevalence is expected to be 13.8
million. AD is the sixth leading cause of death in the United States and the fifth leading cause of death
in Americans age 65 years or older. Between 2000 and 2010, the proportion of deaths resulting from
heart disease, stroke, and prostate cancer decreased 16%, 23%, and 8%, respectively, whereas the pro-
portion resulting from AD increased 68%. The number of deaths from AD as determined by official
death certificates (83,494 in 2010) likely underrepresents the number of AD-related deaths in the
United States. A projected 450,000 older Americans with AD will die in 2013, and a large proportion
will die as a result of complications of AD. In 2012, more than 15 million family members and other
unpaid caregivers provided an estimated 17.5 billion hours of care to people with AD and other
dementias, a contribution valued at more than $216 billion. Medicare payments for services to ben-
eficiaries age 65 years and older with AD and other dementias are three times as great as payments for
beneficiaries without these conditions, and Medicaid payments are 19 times as great. Total payments
in 2013 for health care, long-term care, and hospice services for people age 65 years and older with
dementia are expected to be $203 billion (not including the contributions of unpaid caregivers). An
estimated 2.3 million caregivers of peoplewith AD and other dementias live at least 1 hour away from
the care recipient. These “long-distance caregivers” face unique challenges, including difficulty in
assessing the care recipient’s true health condition and needs, high rates of family disagreement
regarding caregiving decisions, and high out-of-pocket expenses for costs related to caregiving.
Out-of-pocket costs for long-distance caregivers are almost twice as high as for local caregivers.
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2013 Alzheimer’s Disease Facts and Figures is a statisti-
cal resource for US data related to Alzheimer’s disease
(AD), the most common type of dementia, as well as other
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Open access under CC BY-NC-the data are contained in the Overview. This information
includes definitions of the various types of dementia and
a summary of current knowledge about AD. Additional
sections address prevalence, mortality, caregiving, and
use and costs of care and services. This special report fo-
cuses on long-distance caregivers of people with AD and
other dementias.
Specific information in this year’s Alzheimer’s Disease
Facts and Figures includes the following:ND license. 
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AD from the National Institute on Aging (NIA) and
the Alzheimer’s Association
 Overall number of Americans with AD nationally and
for each state
 Proportion of women and men with AD and other
dementias
 Estimates of lifetime risk for developing AD
 Number of family caregivers, hours of care provided,
economic value of unpaid care nationally and for
each state, and the impact of caregiving on caregivers
 Number of deaths resulting fromAD nationally and for
each state, and death rates by age
 Use and costs of health care, long-term care, and
hospice care for people with AD and other dementias
 Number of long-distance caregivers and the special
challenges they face
This report frequently cites statistics that apply to
individualswith all types of dementia.Whenpossible, specific
information about AD is provided; in other cases, the refer-
encemay be amore general one of “AD and other dementias.”2. Overview of AD
AD is the most common type of dementia.Dementia is an
umbrella term that describes a variety of diseases and condi-
tions that develop when nerve cells in the brain (called neu-
rons) die or no longer function normally. The death or
malfunction of neurons causes changes in one’s memory, be-
havior, and ability to think clearly. In AD, these brain
changes eventually impair an individual’s ability to carry
out such basic bodily functions as walking and swallowing.
AD is ultimately fatal.
2.1. Dementia: Definition and specific types
Physicians often define dementia based on the criteria
given in the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) [1]. To meet DSM-IV
criteria for dementia, the following are required:
 Symptoms must include decline in memory and in at
least one of the following cognitive abilities:
1. Ability to speak coherently or understand spoken or
written language
2. Ability to recognize or identify objects, assuming
intact sensory function
3. Ability to perform motor activities, assuming intact
motor abilities and sensory function and compre-
hension of the required task
4. Ability to think abstractly, make sound judgments,
and plan and carry out complex tasks
 The decline in cognitive abilities must be severe
enough to interfere with daily life.
In May 2013, the American Psychiatric Association is ex-
pected to release DSM-5. This new version of DSM is ex-pected to incorporate dementia into the diagnostic
category of major neurocognitive disorder.
To establish a diagnosis of dementia usingDSM-IV, a phy-
sician must determine the cause of the individual’s symp-
toms. Some conditions have symptoms that mimic
dementia but that, unlike dementia, may be reversed with
treatment. An analysis of 39 articles describing 5620 people
with dementialike symptoms reported that 9% had poten-
tially reversible dementia [2]. Common causes of potentially
reversible dementia are depression, delirium, side effects
from medications, thyroid problems, certain vitamin defi-
ciencies and excessive use of alcohol. In contrast, AD and
other dementias are caused by damage to neurons that can-
not be reversed with current treatments.
When an individual has dementia, a physician must
conduct tests to identify the form of dementia that is causing
symptoms. Different types of dementia are associated with
distinct symptom patterns and brain abnormalities, as
described in Table 1. However, increasing evidence from
long-term observational and autopsy studies indicates that
many people with dementia have brain abnormalities associ-
atedwithmore than one type of dementia [3–7]. This is called
mixed dementia and is most often found in individuals of
advanced age.2.2. Alzheimer’s disease
AD was first identified more than 100 years ago, but
research into its symptoms, causes, risk factors, and treat-
ment has gained momentum only during the past 30 years.
Although research has revealed a great deal about AD, the
precise changes in the brain that trigger the development
of AD, and the order in which they occur, largely remain un-
known. The only exceptions are certain rare, inherited forms
of the disease caused by known genetic mutations.
2.2.1. Symptoms of AD
AD affects people in different ways. The most common
symptom pattern begins with a gradually worsening ability
to remember new information. This symptom occurs
because the first neurons to die and malfunction are usually
neurons in brain regions involved in forming new memories.
As neurons in other parts of the brain malfunction and die,
individuals experience other difficulties. The following are
common symptoms of AD:
 Memory loss that disrupts daily life
 Challenges in planning or solving problems
 Difficulty completing familiar tasks at home, at work,
or at leisure
 Confusion with time or place
 Trouble understanding visual images and spatial rela-
tionships
 New problems with words in speaking or writing
 Misplacing things and losing the ability to retrace steps
 Decreased or poor judgment
Table 1
Common types of dementia and their typical characteristics
Type of dementia Characteristics
AD Most common type of dementia; accounts for an estimated 60% to 80% of cases.
Difficulty remembering names and recent events is often an early clinical symptom; apathy and depression are also often early
symptoms. Later symptoms include impaired judgment, disorientation, confusion, behavior changes, and difficulty
speaking, swallowing, and walking.
New criteria and guidelines for diagnosing ADwere proposed and published in 2011. They recommend that AD be considered
a disease that begins well before the development of symptoms.
Hallmark brain abnormalities are deposits of the protein fragment amyloid beta (plaques) and twisted strands of the protein tau
(tangles), as well as evidence of nerve cell damage and death in the brain.
Vascular dementia Previously known as multi-infarct or poststroke dementia, vascular dementia is less common as a sole cause of dementia
than AD.
Impaired judgment or ability to make plans is more likely to be the initial symptom, as opposed to the memory loss often
associated with the initial symptoms of AD.
Vascular dementia occurs because of brain injuries such as microscopic bleeding and blood vessel blockage. The location of
the brain injury determines how the individual’s thinking and physical functioning are affected.
In the past, evidence of vascular dementia was used to exclude a diagnosis of AD (and vice versa). That practice is no longer
considered consistent with pathological evidence, which shows that the brain changes of both types of dementia can be
present simultaneously. When any two or more types of dementia are present at the same time, the individual is considered
to have mixed dementia.
DLB People with DLB have some of the symptoms common in AD, but are more likely than people with AD to have initial or early
symptoms such as sleep disturbances, well-formed visual hallucinations, and muscle rigidity or other parkinsonian
movement features.
Lewy bodies are abnormal aggregations (or clumps) of the protein alpha-synuclein. When they develop in a part of the brain
called the cortex, dementia can result. Alpha-synuclein also aggregates in the brains of people with PD, but the aggregates
may appear in a pattern that is different from DLB.
The brain changes of DLB alone can cause dementia, or they can be present at the same time as the brain changes of AD and/or
vascular dementia, with each entity contributing to the development of dementia. When this happens, the individual is said
to have mixed dementia.
FTLD Includes dementias such as behavioral-variant FTLD, primary progressive aphasia, Pick’s disease, and progressive
supranuclear palsy.
Typical symptoms include changes in personality and behavior, and difficulty with language.
Nerve cells in the front and side regions of the brain are especially affected. No distinguishing microscopic abnormality is
linked to all cases.
The brain changes of behavioral-variant FTLD may be present at the same time as the brain changes of AD, but people with
behavioral-variant FTLD generally develop symptoms at a younger age (at about age 60) and survive for fewer years than
those with AD.
Mixed dementia Characterized by the hallmark abnormalities of AD and another type of dementia—most commonly vascular dementia, but
also other types, such as DLB.
Recent studies suggest that mixed dementia is more common than previously thought.
PD As PD progresses, it often results in a severe dementia similar to DLB or AD.
Problems with movement are a common symptom early in the disease.
Alpha-synuclein aggregates are likely to begin in an area deep in the brain called the substantia nigra. The aggregates are
thought to cause degeneration of the nerve cells that produce dopamine.
The incidence of PD is about one-tenth that of AD.
Creutzfeldt-Jakob disease Rapidly fatal disorder that impairs memory and coordination, and causes behavior changes.
Results from an infectious misfolded protein (prion) that causes other proteins throughout the brain to misfold and thus
malfunction.
Variant Creutzfeldt-Jakob disease is believed to be caused by consumption of products from cattle affected by mad cow
disease.
Normal pressure hydrocephalus Symptoms include difficulty walking, memory loss, and inability to control urination.
Caused by the buildup of fluid in the brain.
Can sometimes be corrected with surgical installation of a shunt in the brain to drain excess fluid.
Abbreviations: AD, Alzheimer’s disease; DLB, Dementia with Lewy bodies; FTLD, Frontotemporal lobar degeneration; PD, Parkinson’s disease.
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 Changes in mood and personality
For more information about symptoms of AD, visit www.
alz.org/10signs.Individuals progress from mild AD to moderate and
severe disease at different rates. As the disease progresses,
the individual’s cognitive and functional abilities decline.
In advanced AD, people need help with basic activities of
daily living (ADLs), such as bathing, dressing, eating, and
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lose their ability to communicate, fail to recognize loved
ones, and become bed-bound and reliant on around-the-
clock care. When an individual has difficulty moving
because of AD, they are more vulnerable to infections,
including pneumonia (infection of the lungs). AD-related
pneumonia is often a contributing factor to the death of peo-
ple with AD.
2.2.2. Diagnosis of AD
A diagnosis of AD is most commonlymade by an individ-
ual’s primary care physician. The physician obtains a medi-
cal and family history, including psychiatric history and
history of cognitive and behavioral changes. The physician
also asks a family member or other person close to the indi-
vidual to provide input. In addition, the physician conducts
cognitive tests and physical and neurological examinations,
and may request that the individual undergo magnetic reso-
nance imaging. Magnetic resonance images can help iden-
tify brain changes, such as the presence of a tumor or
evidence of a stroke, that could explain the individual’s
symptoms.
2.2.3. A modern diagnosis of AD: Proposed new criteria
and guidelines
In 2011, the NIA and the Alzheimer’s Association
proposed new criteria and guidelines for diagnosing AD
[8–11]. These criteria and guidelines updated diagnostic
criteria and guidelines published in 1984 by the
Alzheimer’s Association and the National Institute of
Neurological Disorders and Stroke. In 2012, the NIA and
the Alzheimer’s Association also proposed new guidelines
to help pathologists describe and categorize the brain
changes associated with AD and other dementias [12].
It is important to note that these are proposed criteria and
guidelines. More research is needed, especially research
about biomarkers, before the criteria and guidelines can be
used in clinical settings, such as in a doctor’s office.
2.2.3.1. Differences between the original and new criteria
The 1984 diagnostic criteria and guidelines were based
chiefly on a doctor’s clinical judgment about the cause of
an individual’s symptoms, taking into account reports from
the individual, family members, and friends; results of cog-
nitive tests; and general neurological assessment. The new
criteria and guidelines incorporate two notable changes.
First, they identify three stages of AD, with the first occur-
ring before symptoms such as memory loss develop. In
contrast, for AD to be diagnosed using the 1984 criteria,
memory loss and a decline in thinking abilities severe
enough to affect daily life must have already occurred.
Second, they incorporate biomarker tests. A biomarker is
a biological factor that can be measured to indicate the pres-
ence or absence of disease, or the risk of developing a dis-
ease. For example, blood glucose level is a biomarker of
diabetes; cholesterol level is a biomarker of heart diseaserisk. Levels of certain proteins in fluid (e.g., levels of amy-
loid beta [Ab] and tau in the cerebrospinal fluid [CSF] and
blood) are among several factors being studied as possible
biomarkers for Alzheimer’s.
2.2.3.2. The three stages of AD proposed by the new criteria
and guidelines
The three stages of AD proposed by the new criteria and
guidelines are preclinical AD, mild cognitive impairment
(MCI) due to AD, and dementia due to AD. These stages
are different from the stages now used to describe AD.
The 2011 criteria proposed that AD begins before the devel-
opment of symptoms, and that new technologies have the po-
tential to identify brain changes that precede the
development of symptoms. Using the new criteria, an indi-
vidual with these early brain changes would be said to
have preclinical AD or MCI due to AD, and those with
symptoms would be said to have dementia due to AD. De-
mentia due to AD would encompass all stages of AD com-
monly described today, from mild to moderate to severe.
2.2.3.2.1. Preclinical AD
In the preclinical AD stage, individuals have measurable
changes in the brain, CSF, and/or blood (biomarkers) that
indicate the earliest signs of disease, but they have not yet
developed symptoms such as memory loss. This preclinical
or presymptomatic stage reflects current thinking that AD-
related brain changes may begin 20 years or more before
symptoms occur. Although the new criteria and guidelines
identify preclinical disease as a stage of AD, they do not
establish diagnostic criteria that doctors can use now. Rather,
they state that additional research on biomarker tests is
needed before this stage of AD can be diagnosed.
2.2.3.2.2. MCI due to AD
Individuals with MCI have mild but measurable changes
in thinking abilities that are noticeable to the person affected
and to family members and friends, but that do not affect the
individual’s ability to carry out everyday activities. Studies
indicate that as many as 10% to 20% of people age 65 or
older have MCI [13–15]. As many as 15% of people
whose MCI symptoms cause them enough concern to
contact their doctor’s office for an exam go on to develop
dementia each year. Nearly half of all people who have
visited a doctor about MCI symptoms will develop
dementia in 3 or 4 years [16].
When MCI is identified through community sampling, in
which individuals in a community who meet certain criteria
are assessed regardless of whether they have memory or cog-
nitive complaints, the estimated rate of progression to AD is
slightly less—up to 10% per year [17]. Further cognitive de-
cline is more likely among individuals whose MCI involves
memory problems than among thosewhoseMCI does not in-
volve memory problems. Over 1 year, most individuals with
MCI who are identified through community sampling re-
main cognitively stable. Some, primarily those without
memory problems, experience an improvement in cognition
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some people with MCI develop dementia and others do
not. When an individual with MCI goes on to develop de-
mentia, many scientists believe the MCI is actually an early
stage of the particular form of dementia, rather than a sepa-
rate condition.
When accurate biomarker tests for AD have been identi-
fied, the new criteria and guidelines recommend biomarker
testing for people with MCI to discover whether they have
brain changes that put them at high risk of developing AD
and other dementias. If it can be shown that changes in the
brain, CSF, and/or blood are caused by physiological pro-
cesses associated with AD, the new criteria and guidelines
recommend a diagnosis of MCI due to AD.
2.2.3.2.3. Dementia due to AD
Dementia due to AD is characterized by memory, think-
ing, and behavioral symptoms that impair a person’s ability
to function in daily life and that are caused by AD-related
brain changes.
2.2.3.3. Biomarker tests
The new criteria and guidelines identify two biomarker
categories: (1) biomarkers showing the level of Ab accumu-
lation in the brain and (2) biomarkers showing that neurons
in the brain are injured or actually degenerating.
Many researchers believe that future treatments to slow or
stop the progression of AD and to preserve brain function
(called disease-modifying treatments) will be most effective
when administered during the preclinical and MCI stages of
the disease. Biomarker tests will be essential to identify
which individuals are in these early stages and should
receive disease-modifying treatment. These tests also will
be critical for monitoring the effects of treatment. At this
time, however, more research is needed to validate the accu-
racy of biomarkers and to understand more completely
which biomarker test or combination of tests is most
effective in diagnosing AD. The most effective test or com-
bination of tests may differ, depending on the stage of the
disease and the type of dementia [19].
2.2.4. Changes in the brain that are associated with AD
Many experts believe that AD, like other common
chronic diseases, develops as a result of multiple factors
rather than a single cause. In AD, these multiple factors
are a variety of brain changes that may begin 20 years or
more before symptoms appear. Increasingly, the time
between the initial brain changes of AD and the symptoms
of advanced AD is considered by scientists to represent the
continuum of AD. At the start of the continuum, the individ-
ual is able to function normally despite these brain changes.
Further along the continuum, the brain can no longer
compensate for the neuronal damage that has occurred,
and the individual shows subtle decline in cognitive func-
tion. In some cases, physicians identify this point in the con-
tinuum as MCI. Toward the end of the continuum, the
damage to and death of neurons is so significant that theindividual shows obvious cognitive decline, including symp-
toms such as memory loss or confusion as to time or place.
At this point, physicians following the 1984 criteria and
guidelines for AD would diagnose the individual as having
AD. The 2011 criteria and guidelines propose that the entire
continuum, not just the symptomatic points on the contin-
uum, represents AD. Researchers continue to explore why
some individuals who have brain changes associated with
the earlier points of the continuum do not go on to develop
the overt symptoms of the later points of the continuum.
These and other questions reflect the complexity of the
brain. A healthy adult brain has 100 billion neurons, each
with long, branching extensions. These extensions enable
individual neurons to form specialized connections with
other neurons. At such connections, called synapses, infor-
mation flows in tiny chemical pulses released by one neuron
and detected by the receiving neuron. The brain contains
about 100 trillion synapses that allow signals to travel rap-
idly through the brain’s circuits, creating the cellular basis
of memories, thoughts, sensations, emotions, movements,
and skills. AD interferes with the proper functioning of
neurons and synapses.
Among the brain changes believed to contribute to the de-
velopment of AD are the accumulation of the protein Ab out-
side neurons in the brain (called Ab plaques) and the
accumulation of an abnormal form of the protein tau inside
neurons (called tau tangles). In AD, information transfer at
synapses begins to fail, the number of synapses declines, and
neurons eventually die. The accumulation of Ab is believed
to interfere with the neuron-to-neuron communication at syn-
apses and to contribute to cell death. Tau tangles block the
transport of nutrients and other essential molecules in the neu-
ron and are also believed to contribute to cell death. The brains
of people with advanced AD show dramatic shrinkage from
cell loss and widespread debris from dead and dying neurons.
2.2.5. Genetic mutations that cause AD
The only known cause of AD is genetic mutation—an
abnormal change in the sequence of chemical pairs inside
genes. A small percentage of AD cases, probably fewer
than 1%, are caused by three known genetic mutations.
These mutations involve the gene for the amyloid precursor
protein and the genes for the presenilin 1 and presenilin 2
proteins. Inheriting any of these genetic mutations guaran-
tees that an individual will develop AD. In such individuals,
disease symptoms tend to develop before age 65, sometimes
as early as age 30. People with these genetic mutations are
said to have dominantly inherited AD.
The development and progression of AD in these individ-
uals is of great interest to researchers because the changes
occurring in the brain of these individuals also occur in indi-
viduals with the more common late-onset AD (in which
symptoms develop at age 65 or older). Future treatments
that are effective in people with dominantly inherited AD
may provide clues to effective treatments for people with
late-onset disease.
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wide network of research centers investigating disease
progression in people with a gene for dominantly inherited
AD who have not yet developed symptoms. Dominantly
Inherited Alzheimer Network researchers have found a pat-
tern of brain changes in these individuals. The pattern begins
with decreased levels of Ab in the CSF (the fluid surround-
ing the brain and spinal cord), followed by increased levels
of the protein tau in CSF and increased levels of Ab in the
brain. As the disease progresses, the brain’s ability to use
glucose, its main fuel source, decreases. This decreased
glucose metabolism is followed by impairment of a type of
memory called episodic memory, and then a worsening of
cognitive skills, called global cognitive impairment [20].
Whether this pattern of changes will also hold true for indi-
viduals at high risk for late-onset AD or younger onset AD
(in which symptoms develop before age 65) that is not dom-
inantly inherited requires further study.
2.2.6. Risk factors for AD
Many factors contribute to one’s likelihood of developing
AD. The greatest risk factor for AD is advancing age, but AD
is not a typical part of aging. Most people with AD are diag-
nosed at age 65 or older. However, people younger than 65
can also develop the disease, although this is much more
rare. Advancing age is not the only risk factor for AD. The
following sections describe other risk factors.
2.2.6.1. Family history
Individuals who have a parent, brother, or sister with AD
are more likely to develop the disease than those who do not
have a first-degree relative with AD [21–23]. Those who
have more than one first-degree relative with AD are at
even higher risk of developing the disease [24]. When
diseases run in families, heredity (genetics), shared environ-
mental and lifestyle factors, or both, may play a role. The
increased risk associated with having a family history of
AD is not entirely explained by whether the individual has
inherited the apolipoprotein E (APOE) ε4 risk gene.
2.2.6.2. APOE ε4 gene
The APOE gene provides the blueprint for a protein that
carries cholesterol in the bloodstream. Everyone inherits one
form of the APOE gene—ε2, ε3 or ε4—from each parent.
The ε3 form is the most common [25], with about 60% of
the U.S. population inheriting ε3 from both parents [26].
The ε2 and ε4 forms are much less common. An estimated
20% to 30% of individuals in the United States have one
or two copies of the ε4 form [25,26]; approximately 2% of
the U.S. population has two copies of ε4 [26]. The remaining
10% to 20% have one or two copies of ε2.
Having the ε3 form is believed neither to increase nor
decrease one’s risk of AD, whereas having the ε2 form
may decrease one’s risk. The ε4 form, however, increases
the risk of developing AD and of developing it at a younger
age. Those who inherit two ε4 genes have an even higher
risk. Researchers estimate that between 40% and 65% ofpeople diagnosed with AD have one or two copies of the
APOE ε4 gene [25,27,28].
Inheriting the APOE ε4 gene does not guarantee that an
individual will develop AD. This is also true for several
genes that appear to increase risk of AD but have a limited
overall effect in the population because they are rare or in-
crease risk only slightly. Many factors other than genetics
are believed to contribute to the development of AD.
2.2.6.3. Mild cognitive impairment
MCI is a condition in which an individual has mild but
measurable changes in thinking abilities that are noticeable
to the person affected and to family members and friends,
but that do not affect the individual’s ability to carry out
everyday activities. PeoplewithMCI, especiallyMCI involv-
ing memory problems, are more likely to develop AD and
other dementias than people without MCI. However, MCI
does not always lead to dementia. For some individuals,
MCI reverts to normal cognition on its own or remains stable.
In other cases, such as when a medication causes cognitive
impairment,MCI is diagnosedmistakenly. Therefore, it’s im-
portant that people experiencing cognitive impairment seek
help as soon as possible for diagnosis and possible treatment.
The 2011 proposed criteria and guidelines for diagnosis
of AD [8–11] suggest that, in some cases, MCI is actually
an early stage of AD or another dementia.
2.2.6.4. Cardiovascular disease risk factors
Increasing evidence suggests that the health of the brain is
linked closely to the overall health of the heart and blood
vessels. The brain is nourished by one of the body’s richest
networks of blood vessels. A healthy heart helps ensure that
enough blood is pumped through these blood vessels to the
brain, and healthy blood vessels help ensure that the brain
is supplied with the oxygen- and nutrient-rich blood it needs
to function normally.
Many factors that increase the risk of cardiovascular
disease are also associated with a higher risk of developing
AD and other dementias. These factors include smoking
[29–31], obesity (especially in midlife) [32–37], diabetes
mellitus [31,38–41], high cholesterol in midlife [34,42],
and hypertension in midlife [34,37,43–45]. A pattern that
has emerged from these findings, taken together, is that
dementia risk may increase with the presence of the
metabolic syndrome, a collection of conditions occurring
together—specifically, three or more of the following:
hypertension, high blood glucose, central obesity (obesity
in which excess weight is carried predominantly at the
waist), and abnormal blood cholesterol levels [40].
Conversely, factors that protect the heart may protect the
brain and reduce the risk of developing AD and other demen-
tias. Physical activity [40,46–48] appears to be one of these
factors. In addition, emerging evidence suggests that
consuming a diet that benefits the heart, such as one that is
low in saturated fats and rich in vegetables and vegetable-
based oils, may be associated with reduced AD and dementia
risk [40].
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disease risk factors are modifiable—that is, they can be
changed to decrease the likelihood of developing cardiovas-
cular disease and, possibly, the cognitive decline associated
with AD and other forms of dementia.
2.2.6.5. Education
People with fewer years of education are at higher risk for
AD and other dementias than those with more years of for-
mal education [49–53]. Some researchers believe that
having more years of education builds a “cognitive
reserve” that enables individuals to compensate more fully
for changes in the brain that could result in symptoms of
AD or another dementia [52,54–56]. According to the
cognitive reserve hypothesis, having more years of
education increases the connections between neurons in
the brain and enables the brain to compensate for the early
brain changes of AD by using alternate routes of neuron-
to-neuron communication to complete a cognitive task. In
addition, some scientists believe that the increased risk of
dementia among those with lower educational attainment
may be explained by other factors common to people in
lower socioeconomic groups, such as increased risk for
disease in general and less access to medical care [57].
2.2.6.6. Social and cognitive engagement
Additional studies suggest that other modifiable factors,
such as remaining mentally [58–60] and socially active,
may support brain health and possibly reduce the risk of
AD and other dementias [61–68]. Remaining socially and
cognitively active may help build cognitive reserve, but
the exact mechanism by which this may occur is
unknown. Compared with cardiovascular disease risk
factors, there are fewer studies of the association between
social and cognitive engagement and the likelihood of
developing AD and other dementias. More research is
needed to understand more completely how social and
cognitive engagement may affect biological processes to
reduce risk.
2.2.6.7. Traumatic brain injury (TBI)
Moderate and severe TBI increase the risk of developing
AD and other dementias [69]. TBI is the disruption of nor-
mal brain function caused by a blow or jolt to the head or
penetration of the skull by a foreign object. Not all blows
or jolts to the head disrupt brain function. Moderate TBI is
defined as a head injury resulting in loss of consciousness
or posttraumatic amnesia that lasts more than 30 minutes.
If loss of consciousness or posttraumatic amnesia lasts
more than 24 hours, the injury is considered severe. Half
of all moderate or severe TBIs are caused by motor vehicle
accidents [70]. Moderate TBI is associated with twice the
risk of developing AD and other dementias compared with
no head injury, and severe TBI is associated with 4.5 times
the risk of developing AD [71]. These increased risks have
not been studied for individuals experiencing occasional
mild head injury or any number of common minor mishapssuch as bumping one’s head against a shelf or an open cab-
inet door.
Groups that experience repeated head injuries, such as
boxers, football players [72], and combat veterans, are at
higher risk of dementia, cognitive impairment, and neurode-
generative disease than individuals who experience no head
injury [73–78]. Emerging evidence suggests that even
repeated mild TBI might promote neurodegenerative
disease [78]. Some of these neurodegenerative diseases,
such as chronic traumatic encephalopathy, can only be
distinguished from AD at autopsy.
2.2.7. Treatment of AD
2.2.7.1. Pharmacological treatment
Pharmacological treatments are treatments in which
medication is administered to stop an illness or treat its
symptoms. None of the treatments available today for
AD slows or stops the death and malfunction of neurons
in the brain that cause AD symptoms and make the dis-
ease fatal. However, dozens of drugs and therapies aimed
at slowing or stopping brain cell death and malfunction
are being studied worldwide. Five drugs have been ap-
proved by the U.S. Food and Drug Administration that im-
prove symptoms of AD temporarily by increasing the
amount of chemicals called neurotransmitters in the
brain. The effectiveness of these drugs varies across the
population.
Despite the lack of disease-modifying therapies, studies
have shown consistently that active medical management
of AD and other dementias can improve quality of life
through all stages of the disease for individuals with demen-
tia and their caregivers [79–81]. Active management
includes (1) appropriate use of available treatment options;
(2) effective management of coexisting conditions; (3)
coordination of care among physicians, other health care
professionals, and lay caregivers; (4) participation in
activities and/or adult daycare programs; and (5) taking
part in support groups and supportive services.
2.2.7.2. Nonpharmacological therapy
Nonpharmacological therapies are those that use
approaches other than medication, such as cognitive training
and behavioral interventions. As with pharmacological ther-
apies, no nonpharmacological therapies have been shown to
alter the course of AD, although some are used with the goal
of maintaining cognitive function or helping the brain
compensate for impairments. Other nonpharmacological
therapies are intended to improve quality of life or reduce
behavioral symptoms such as depression, apathy, wander-
ing, sleep disturbances, agitation, and aggression. A wide
range of nonpharmacological interventions have been
proposed or studied, although few have sufficient evidence
supporting their effectiveness. There is some evidence that
specific nonpharmacological therapies may improve or sta-
bilize cognitive function, performance of daily activities,
behavior, mood, and quality of life [82].
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Millions of Americans have AD and other dementias. The
number of Americans with AD and other dementias will
grow each year as the number and proportion of the U.S.
population age 65 and older continue to increase. The
number will escalate rapidly in coming years as the baby
boom generation ages.
Estimates from selected studies on the prevalence and
characteristics of people with AD and other dementias
vary depending on how each study was conducted. Data
from several studies are used in this section. Most estimates
are from a new study using the same methods as the study
that provided estimates in previous years’ Facts and Figures
reports, but with updated data [83].A1 Although some of the
estimates are slightly different than estimates in previous
Facts and Figures reports, researchers consider them to be
statistically indistinguishable from previous estimates
when accounting for margins of error.
3.1. Prevalence of AD and other dementias
An estimated 5.2 million Americans of all ages have
AD in 2013. This includes an estimated 5.0 million people
age 65 and older [83]A1 and approximately 200,000 indi-
viduals younger than age 65 who have younger onset AD
[84].
 One in nine people age 65 and older (11%) has AD.A2
 About one-third of people age 85 and older (32%) have
AD [83].
 Of those with AD, an estimated 4% are younger than
age 65, 13% are 65 to 74 years old, 44% are 75 to 84
years old, and 38% are 85 years or older [83].A3
The estimated prevalence for people age 65 and older
comes from a new study using the latest data from the
2010 U.S. Census and the Chicago Health and Aging
Project (CHAP), a population-based study of chronic health
diseases of older people. Although this estimate is slightly
lower than the estimate presented in previous Facts and
Figures reports, it does not represent a real change in prev-
alence. According to the lead author of both the original
and the new studies on the prevalence of Alzheimer’s, “Sta-
tistically, [the estimates] are comparable, and, more impor-
tantly, both old and new estimates continue to show that the
burden [AD] places on the population, short of any effec-
tive preventive interventions, is going to continue to in-
crease substantially” [83].
In addition to estimates from CHAP, the national preva-
lence of AD and all forms of dementia has been estimated
from other population-based studies, including the Aging,
Demographics, and Memory Study (ADAMS), a nationally
representative sample of older adults [85,86].A4 National
estimates of the prevalence of all forms of dementia are
not available from CHAP; however, based on estimates
from ADAMS, 13.9% of people age 71 and older in the
United States have dementia [85].Prevalence studies such as CHAP and ADAMS are
designed so that all individuals with dementia are detected;
but, in the community, only about half of those who would
meet the diagnostic criteria for AD and other dementias
have received a diagnosis of dementia from a physician
[87]. Because AD is underdiagnosed, half of the estimated
5.2 million Americans with AD may not know they have it.
The estimates from CHAP and ADAMS are based on
commonly accepted criteria for diagnosing AD that have
been used since 1984. In 2009, an expert work group was
convened by the Alzheimer’s Association and the NIA to
recommend updated diagnostic criteria and guidelines, as
described in the Overview. These proposed new criteria
and guidelines were published in 2011 [8–11]. If AD can
be detected earlier, in the stages of preclinical AD and/or
MCI due to AD, as defined by the 2011 criteria, the
number of people reported to have AD would be much
larger than what is presented in this report.
3.1.1. Prevalence of AD and other dementias in women and
men
More women than men have AD and other dementias.
Almost two-thirds of Americans with AD are women
[83].A5 Of the 5 million people age 65 years and older
with AD in the United States, 3.2 million are women and
1.8 million are men.A5 Based on estimates from ADAMS,
16% of women age 71 years and older have AD and other
dementias compared with 11% of men [85,88].
The larger proportion of older women who have AD and
other dementias is explained primarily by the fact that
women live longer, on average, than men [88,89].
Many studies of the age-specific incidence (development
of new cases) of AD [50,51,89–93] or any dementia
[49,50,90,91,94] have found no significant difference by
sex. Thus, women are not more likely than men to develop
dementia at any given age.
3.1.2. Prevalence of AD and other dementias by years of
education
People with fewer years of education appear to be at
higher risk for AD and other dementias than those with
more years of education [49–53]. Some of the possible
reasons are explained in the Risk Factors for AD section
of the Overview.
3.1.3. Prevalence of AD and other dementias in older
whites, blacks, and Hispanics
Although most people in the United States living with AD
and other dementias are non-Hispanic whites, older blacks
and Hispanics are proportionately more likely than older
whites to have AD and other dementias [95,96]. Data
indicate that, in the United States, older blacks are probably
about twice as likely to have AD and other dementias as
older whites [97], and Hispanics are about 1.5 times as likely
to have AD and other dementias as older whites [98]. Fig. 1
shows the estimated prevalence for each group, by age.
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ence of genetic risk factors on AD and other dementias,
genetic factors do not appear to account for these large
prevalence differences across racial groups [99]. Instead,
health conditions such as high blood pressure and diabetes
mellitus, which may increase one’s risk for AD and other
dementias, are believed to account for these differences
because they are more prevalent in black and Hispanic peo-
ple. Lower levels of education and other socioeconomic
characteristics in these communities may also increase
risk. Some studies suggest that differences based on race
and ethnicity do not persist in detailed analyses that
account for these factors [50,85].
There is evidence that missed diagnoses are more
common among older blacks and Hispanics than among
older whites [100,101]. A recent study of Medicare
beneficiaries found that AD and other dementias had been
diagnosed in 8.2% of white beneficiaries, 11.3% of black
beneficiaries, and 12.3% of Hispanic beneficiaries [102].
Although rates of diagnosis were higher among blacks
than among whites, this difference was not as great as would
be expected based on the estimated differences found in
prevalence studies, which are designed to detect all people
who have dementia.3.2. Incidence and lifetime risk of AD
While prevalence is the number of existing cases of a dis-
ease in a population at a given time, incidence is the number
of new cases of a disease that develop in a given time period.
The estimated annual incidence (rate of developing disease in
1 year) of AD appears to increase dramatically with age, from
approximately 53 new cases/1000 people age 65 to 74 years,
to 170 new cases/1000 people age 75 to 84 years, to 231 new
cases/1000 people age 85 years and older (the “oldest-old”)
[103]. Some studies have found that incidence rates decrease
after age 90, but these findings are controversial. One analysis
indicates that dementia incidence may continue to increase
and that previous observations of a leveling off of incidence
among the oldest-old may be a result of sparse data for this
group [104]. Because of the increasing number of peopleFig. 1. Proportion of people age 65 years and older with Alzheimer’s disease anage 65 and older in the United States, the annual number of
new cases of Alzheimer’s and other dementias is projected
to double by 2050 [103]:
 Every 68 seconds, someone in the United States de-
velops AD.A6
 By midcentury, someone in the United States will de-
velop the disease every 33 seconds.A6
Lifetime risk is the probability that someone of a given
age will develop a condition during their remaining life
span. Data from the Framingham Study were used to esti-
mate lifetime risks of AD and of any dementia [105].A7
The study found that 65-year-old women without dementia
had a 20% chance of developing dementia during the re-
mainder of their lives (estimated lifetime risk) compared
with a 17% chance for men. As shown in Fig. 2, for AD spe-
cifically, the estimated lifetime risk at age 65 was nearly one
in five (17.2%) for women compared with one in 11 (9.1%)
for men [105].A8 As noted previously, these differences in
lifetime risks between women and men are largely a result
of women’s longer life expectancy.
The definition of AD and other dementias used in the Fra-
mingham Study required documentation of moderate to
severe disease as well as symptoms lasting a minimum of
6 months. Using a definition that also includes milder dis-
ease and disease of less than a 6-month duration, lifetime
risks of AD and other dementias would be much higher
than those estimated by this study.3.3. Estimates of the number of people with AD, by state
Table 2 summarizes the projected total number of people
age 65 and older with AD, by state, for 2000, 2010, and
2025.A9 The percentage changes in the number of people
with AD between 2000 and 2010 and between 2000 and
2025 are also shown. Note that the total number of people
with AD is larger for states with larger populations, such
as California and New York. Comparable estimates and pro-
jections for other types of dementia are not available.
As shown in Fig. 3 [106], between 2000 and 2025, some
states and regions across the country are expected tod other dementias. Created from data from Gurland and colleagues [98].
Fig. 2. Estimated lifetime risks for Alzheimer’s disease, by age and sex, from the Framingham Study. Created from data from Seshadri and colleagues [105].
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bers of people with AD as a result of increases in the pro-
portion of the population age 65 years and older. The South
and West are expected to experience 50% and greater in-
creases in numbers of people with AD between 2000 and
2025. Some states (Alaska, Colorado, Idaho, Nevada,
Utah, and Wyoming) are projected to experience a doubling
(or more) of the number of people with AD. Although the
projected increases in the Northeast are not nearly as
marked as those in other regions of the United States, it
should be noted that this region of the country currently
has a large proportion of people with AD relative to other
regions because this region already has a high proportion
of people age 65 and older. The increasing number of indi-
viduals with AD will have a marked impact on states’
health care systems, as well as on families and caregivers.3.4. Looking to the future
The number of Americans surviving into their 80s,
90s, and beyond is expected to grow dramatically as a re-
sult of advances in medicine and medical technology, as
well as social and environmental conditions [107]. In ad-
dition, a large segment of the American population—the
baby boom generation—has begun to reach the age range
of elevated risk for AD and other dementias, with the
first baby boomers having reached age 65 in 2011. By
2030, the segment of the U.S. population age 65 and
older is expected to increase dramatically, and the esti-
mated 72 million older Americans will make up approx-
imately 20% of the total population (up from 13% in
2010) [107].
As the number of older Americans increases rapidly, so,
too, will the numbers of new and existing cases of AD, as
shown in Fig. 4 [83].A10
 In 2000, there were an estimated 411,000 new cases of
AD. For 2010, that number was estimated to be
454,000 (a 10% increase); by 2030, it is projected tobe 615,000 (a 50% increase from 2000); and by
2050, it is projected to be 959,000 (a 130% increase
from 2000) [103].
 By 2025, the number of people age 65 and older with
AD is estimated to reach 7.1 million—a 40% increase
from the 5 million age 65 and older currently affected
[83].A11
 By 2050, the number of people age 65 and older with
AD may nearly triple, from 5 million to a projected
13.8 million, barring the development of medical
breakthroughs to prevent, slow, or stop the disease
[83].A10 Previous estimates suggest that this number
may be as high as 16 million [108].A12
Longer life expectancies and aging baby boomers will
also increase the number and percentage of Americans
who will be among the oldest-old. Between 2010 and
2050, the oldest-old are expected to increase from 14% of
all people age 65 and older in the United States to 20% of
all people age 65 and older [107], which will result in an ad-
ditional 13 million oldest-old—individuals at the highest
risk for developing AD [107].
 By 2050, the number of Americans age 85 years and
older will nearly quadruple to 21 million [107].
 In 2013, the 85-years-and-older population includes
about 2 million people with AD, or 40% of all people
with AD age 65 and older [83].
 When the first wave of baby boomers reaches age 85
(in 2031), it is projected that more than 3 million peo-
ple age 85 and older are likely to have AD [83].4. Mortality
AD is officially listed as the sixth leading cause of
death in the United States [109]. It is the fifth leading
cause of death for those age 65 and older [109]. However,
it may cause even more deaths than official sources recog-
nize.
Table 2




(in 1000s) with AD
Percentage change in AD
(compared with 2000)
2000 2010 2025 2010 2025
Alabama 84.0 91.0 110.0 8 31
Alaska 3.4 5.0 7.7 47 126
Arizona 78.0 97.0 130.0 24 67
Arkansas 56.0 60.0 76.0 7 36
California 440.0 480.0 660.0 9 50
Colorado 49.0 72.0 110.0 47 124
Connecticut 68.0 70.0 76.0 3 12
Delaware 12.0 14.0 16.0 17 33
District of
Columbia
10.0 9.1 10.0 29 0
Florida 360.0 450.0 590.0 25 64
Georgia 110.0 120.0 160.0 9 45
Hawaii 23.0 27.0 34.0 17 48
Idaho 19.0 26.0 38.0 37 100
Illinois 210.0 210.0 240.0 0 14
Indiana 100.0 120.0 130.0 20 30
Iowa 65.0 69.0 77.0 6 18
Kansas 50.0 53.0 62.0 6 24
Kentucky 74.0 80.0 97.0 8 31
Louisiana 73.0 83.0 100.0 14 37
Maine 25.0 25.0 28.0 0 12
Maryland 78.0 86.0 100.0 10 28
Massachusetts 120.0 120.0 140.0 0 17
Michigan 170.0 180.0 190.0 6 12
Minnesota 88.0 94.0 110.0 7 25
Mississippi 51.0 53.0 65.0 4 27
Missouri 110.0 110.0 130.0 0 18
Montana 16.0 21.0 29.0 31 81
Nebraska 33.0 37.0 44.0 12 33
Nevada 21.0 29.0 42.0 38 100
New Hampshire 19.0 22.0 26.0 16 37
New Jersey 150.0 150.0 170.0 0 13
New Mexico 27.0 31.0 43.0 15 59
New York 330.0 320.0 350.0 23 6
North Carolina 130.0 170.0 210.0 31 62
North Dakota 16.0 18.0 20.0 13 25
Ohio 200.0 230.0 250.0 15 25
Oklahoma 62.0 74.0 96.0 19 55
Oregon 57.0 76.0 110.0 33 93
Pennsylvania 280.0 280.0 280.0 0 0
Rhode Island 24.0 24.0 24.0 0 0
South Carolina 67.0 80.0 100.0 19 49
South Dakota 17.0 19.0 21.0 12 24
Tennessee 100.0 120.0 140.0 20 40
Texas 270.0 340.0 470.0 26 74
Utah 22.0 32.0 50.0 45 127
Vermont 10.0 11.0 13.0 10 30
Virginia 100.0 130.0 160.0 30 60
Washington 83.0 110.0 150.0 33 81
West Virginia 40.0 44.0 50.0 10 25
Wisconsin 100.0 110.0 130.0 10 30
Wyoming 7.0 10.0 15.0 43 114
Abbreviation: AD, Alzheimer’s disease.
NOTE. Created from data from Hebert and colleagues [106].A9
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It is difficult to determine howmany deaths are caused by
AD each year because of the way causes of death arerecorded. According to final data from the National Center
for Health Statistics of the Centers for Disease Control and
Prevention (CDC), 83,494 people died from AD in 2010
(the most recent year for which final data are available)
[109]. The CDC considers a person to have died from AD
if the death certificate lists AD as the underlying cause of
death, defined by the World Health Organization as “the dis-
ease or injury which initiated the train of events leading
directly to death” [110]. However, death certificates for indi-
viduals with AD often list acute conditions such
as pneumonia as the primary cause of death rather than
AD [111–113]. Severe dementia frequently causes
complications such as immobility, swallowing disorders,
and malnutrition that can significantly increase the risk of
other serious conditions that can cause death. One such
condition is pneumonia, which has been found in several
studies to be the most commonly identified cause of death
among elderly people with AD and other dementias
[114,115]. The number of people with AD and other
dementias who die while experiencing these conditions
may not be counted among the number of people who died
from AD according to the CDC definition, even though
AD is likely a contributing cause of death. Thus, it is
likely that AD is a contributing cause of death for more
Americans than is indicated by CDC data.
The situation has been described as a “blurred distinc-
tion between death with dementia and death from demen-
tia” [116]. According to CHAP data, an estimated
400,000 people died with AD in 2010, meaning they
died after developing AD.A13 Furthermore, according to
Medicare data, one-third of all seniors who die in a given
year have been previously diagnosed with AD or another
dementia [102,117]. Although some seniors who die with
AD die from causes unrelated to AD, many of them die
from AD itself or from conditions in which AD was
a contributing cause, such as pneumonia. A recent study
evaluated the contribution of individual common diseases
to death using a national representative sample of older
adults and it found that dementia was the second largest
contributor to death, following heart failure [118]. Thus,
for people who die with AD and other dementias, dementia
is expected to be a significant direct contributor to their
deaths.
In 2013, an estimated 450,000 people in the United States
will die with AD.A13 The true number of deaths caused by
AD is likely to be somewhere between the official estimated
numbers of those dying from AD (as indicated by death cer-
tificates) and those dying with AD (that is, dying after devel-
oping AD). Regardless of the cause of death, among people
age 70 years, 61% of those with AD are expected to die be-
fore age 80 compared with 30% of people without AD [119].4.2. Public health impact of deaths from AD
As the population of the United States ages, AD is be-
coming a more common cause of death. Although deaths
Fig. 3. Projected changes between 2000 and 2025 in Alzheimer’s disease prevalence by state. Created from data from Hebert and colleagues [106].A9
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from AD have increased significantly. Between 2000 and
2010, deaths attributed to AD increased 68% whereas those
attributed to the number one cause of death, heart disease,
decreased 16% (Fig. 5) [109,120]. The increase in the
number and proportion of death certificates listing AD as
the underlying cause of death reflects both changes in
patterns of reporting deaths on death certificates over time
as well as an increase in the actual number of deaths
attributable to AD.
Another way to describe the impact of AD on mortality
is through a statistic known as population attributable risk.
It represents the proportion of deaths (in a specified
amount of time) in a population that may be preventable
if a disease were eliminated. The population attributable
risk of AD on mortality over 5 years in people age 65
and older is estimated to be between 5% and 15%
[121,122], which means that during the next 5 years, 5%
to 15% of all deaths in older people can be attributed
to AD.4.3. State-by-state deaths from AD
Table 3 provides information on the number of deaths re-
sulting from AD by state in 2010, the most recent year for
which state-by-state data are available. This information was
obtained fromdeath certificates and reflects the condition iden-
tified by the physician as the underlying cause of death. The ta-
ble also provides annualmortality rates by state to compare the
risk of death resulting fromADacross stateswith varying pop-
ulation sizes. For the United States as a whole, in 2010, the
mortality rate for ADwas 27 deaths per 100,000 people [109].
4.4. Death rates by age
Although people younger than 65 can develop and die
from AD, the highest risk of death from AD is in people
age 65 or older. As seen in Table 4, death rates for AD in-
crease dramatically with age. Compared with the rate of
death from any cause among people age 65 to 74, death rates
were 2.6 times as high for those age 75 to 84 and 7.4 times as
high for those age 85 and older. For diseases of the heart,
Fig. 4. Projected number of people aged 65 years and older (total and by age group) in the U.S. population with Alzheimer’s disease, 2010 to 2050. Created from
data from Hebert and colleagues [83].A10
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tively. For all cancers, mortality rates were 1.8 times as high
and 2.6 times as high, respectively. In contrast, AD death
rates were 9.3 times as high for people age 75 to 84 and
49.9 times as high for people 85 and older compared with
the AD death rate among people age 65 to 74 [109]. The
high death rate at older ages for AD underscores the lack
of a cure or effective treatments for the disease.
4.5. Duration of illness from diagnosis to death
Studies indicate that people age 65 andolder survive an av-
erage of 4 to 8 years after a diagnosis of AD, yet some live as
long as 20 years with AD [122–127]. This observation
indicates the slow, insidious nature of the progression of
AD. On average, a person with AD will spend more years
(40% of the total number of years with AD) in the most
severe stage of the disease than in any other stage [119].
Much of this time will be spent in a nursing home; nursing
home admission by age 80 is expected for 75% of peopleFig. 5. Percentage changes in selected causes of death (all ages) between 2000 a
National Center for Health Statistics [109,120].with AD compared with only 4% of the general population
[119]. In all, an estimated two-thirds of those dying of demen-
tia do so in nursing homes, compared with 20% of cancer pa-
tients and 28% of people dying from all other conditions
[128]. Thus, the long duration of illness before death contrib-
utes significantly to the public health impact of AD.5. Caregiving
Caregiving refers to attending to another individual’s
health needs and often includes assistance with one or
more ADLs, such as bathing and dressing [129,130]. More
than 15 million Americans provide unpaid care for people
with AD and other dementias.A14
5.1. Unpaid caregivers
Unpaid caregivers are primarily immediate family mem-
bers, but they also may be other relatives and friends. In
2012, these people provided an estimated 17.5 billion hoursnd 2010. HIV, human immunodeficiency virus. Created from data from the
Table 3
Number of deaths and annual mortality rate (per 100,000) as a result of






Alabama 1523 31.9 Montana 302 30.5
Alaska 85 12.0 Nebraska 565 30.9
Arizona 2327 36.4 Nevada 296 11.0
Arkansas 955 32.8 New Hampshire 396 30.1
California 10,856 29.1 New Jersey 1878 21.4
Colorado 1334 26.5 New Mexico 343 16.7
Connecticut 820 22.9 New York 2616 13.5
Delaware 215 23.9 North Carolina 2817 29.5
District of
Columbia
114 18.9 North Dakota 361 53.7
Florida 4831 25.7 Ohio 4109 35.6
Georgia 2080 21.5 Oklahoma 1015 27.1
Hawaii 189 13.9 Oregon 1300 33.9
Idaho 410 26.2 Pennsylvania 3591 28.3
Illinois 2927 22.8 Rhode Island 338 32.1
Indiana 1940 29.9 South Carolina 1570 33.9
Iowa 1411 46.3 South Dakota 398 48.9
Kansas 825 28.9 Tennessee 2440 38.4
Kentucky 1464 33.7 Texas 5209 20.7
Louisiana 1295 28.6 Utah 375 13.6
Maine 502 37.8 Vermont 238 38.0
Maryland 986 17.1 Virginia 1848 23.1
Massachusetts 1773 27.1 Washington 3025 45.0
Michigan 2736 27.7 West Virginia 594 32.1
Minnesota 1451 27.4 Wisconsin 1762 31.0
Mississippi 927 31.2 Wyoming 146 25.9
Missouri 1986 33.2 U.S. total 83,494 27.0
NOTE. Created from data from the National Center for Health Statistics
[109].
Table 4
U.S. Alzheimer’s disease death rates (per 100,000) by age
Age, years 2000 2002 2004 2006 2008 2010
45–54 0.2 0.1 0.2 0.2 0.2 0.3
55–64 2.0 1.9 1.8 2.1 2.2 2.1
65–74 18.7 19.6 19.5 19.9 21.1 19.8
75–84 139.6 157.7 168.5 175.0 192.5 184.5
851 667.7 790.9 875.3 923.4 1002.2 987.1
Rate* 18.1 20.8 22.6 23.7 25.8 25.1
NOTE. Created from data from National Center for Health Statistics
[109].
*Reflects average death rate for ages 45 and older.
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than $216 billion, which is approximately half of the net
value of Walmart sales in 2011 ($419 billion) [131] and
more than eight times the total sales of McDonald’s in
2011 ($27 billion) [132]. Eighty percent of care provided
in the community is provided by unpaid caregivers (most of-
ten family members), whereas fewer than 10% of older
adults receive all their care from paid caregivers [133].
5.1.1. Who are the caregivers?
Several sources have examined the demographic back-
ground of family caregivers of people with AD and other de-
mentias [134].A15 Data from the 2010 Behavioral Risk
Factor Surveillance System (BRFSS) survey conducted in
Connecticut, New Hampshire, New Jersey, New York, and
Tennessee [134] found that 62% of caregivers of people
with AD and other dementias were women; 23% were 65
years of age and older; 50% had some college education
or beyond; 59% were currently employed, a student, or
a homemaker; and 70% were married or in a long-term rela-
tionship [134].
ADAMS,basedonanationally representative subsampleof
older adults from the Health and Retirement Survey [135],
compared two types of caregivers: those caring for people
with dementia and those caring for peoplewith cognitive prob-lems that did not reach the threshold of dementia. The care-
giver groups did not differ significantly by age (60 years vs
61 years, respectively), sex (71% vs 81% female), race (66%
vs 71% non-Hispanic white) or marital status (70% vs 71%
married). Almost half of caregivers took care of parents [136].
The National Alliance for Caregiving (NAC)/AARP
found that 30% of caregivers had children younger than 18
years old living with them; such caregivers are sometimes
called sandwich caregivers because they provide care con-
comitantly for two generations [137].
5.1.2. Ethnic and racial diversity in caregiving
Among caregivers of people with AD and other demen-
tias, the NAC/AARP found the following [137]:
 A greater proportion of white caregivers assist a parent
than caregivers of individuals from other racial/ethnic
groups (54% vs 38%).
 On average, Hispanic and black caregivers spend more
time caregiving (approximately 30 hours/week) than
non-Hispanic white caregivers (20 hours/week) and
Asian caregivers (16 hours/week).
 Hispanic (45%) and black (57%) caregivers are more
likely to experience high burden from caregiving
than whites and Asians (about one-third and one-
third, respectively).
As noted in the Prevalence section of this report, the ra-
cial/ethnic distribution of people with AD will change dra-
matically by 2050. Given the greater likelihood of
acquiring AD among blacks and Hispanics, coupled with
the increasing number of black and Hispanic older adults
by 2050, it can be assumed that family caregivers will be
more ethnically and racially diverse during the next 35 years.
5.1.3. Caregiving tasks
The care provided to people with AD and other dementias
iswide ranging and, in some instances, all encompassing. The
types of dementia care provided are shown in Table 5 [138].
Although the care provided by family members of people
with AD and other dementias is somewhat similar to the help
provided by caregivers of peoplewith other diseases, demen-
tia caregivers tend to provide more extensive assistance.
Family caregivers of people with dementia are more likely
Table 5
Dementia caregiving tasks
Helping with instrumental ADLs, such as household chores, shopping,
preparing meals, providing transportation, arranging for doctor’s
appointments, managing finances and legal affairs and answering the
telephone
Helping the person with AD or other dementias take medications correctly,
either via reminders or direct administration of medications
Helping the person with AD or other dementias adhere to treatment
recommendations for dementia or other medical conditions
Assisting with personal ADLs, such as bathing, dressing, grooming, and
feeding, and helping the person with AD or other dementias walk,
transfer from bed to chair, use the toilet, and manage incontinence
Managing behavioral symptoms of the disease such as aggressive behavior,
wandering, depressive mood, agitation, anxiety, repetitive activity, and
nighttime disturbances [138]
Finding and using support services such as support groups and adult day
service programs
Making arrangements for paid in-home, nursing home, or assisted living
care
Hiring and supervising others who provide care
Assuming additional responsibilities that are not necessarily specific tasks,
such as
 Providing overall management of getting through a day
 Addressing family issues related to caring for a relative with AD,
including communicating with other family members about care
plans, decision making, and arrangements for respite for the main
caregiver
Abbreviations: AD, Alzheimer’s disease; ADL, activity of daily living.
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(Fig. 6). More than half of dementia caregivers report
providing help with getting in and out of bed, and about
one-third of family caregivers provide help to their care re-
cipients with getting to and from the toilet, bathing, manag-
ing incontinence, and feeding (Fig. 6). These findings
suggest the heightened degree of dependency experienced
by some people with AD and other dementias. Fewer care-
givers of other older people report providing help with
each of these types of care [137].
In addition to assisting with ADLs, almost two-thirds of
caregivers of people with AD and other dementias advocateFig. 6. Proportion of caregivers of peoplewith Alzheimer’s disease (AD) and other
activities of daily living in the United States for the year 2009. Created from datafor their care recipient with government agencies and service
providers (64%), and nearly half arrange and supervise paid
caregivers from community agencies (46%). In contrast,
caregivers of other older adults are less likely to advocate
for their family member (50%) and supervise community-
based care (33%) [137]. Caring for a person with dementia
also means managing symptoms that family caregivers of
people with other diseases may not face, such as neuropsy-
chiatric symptoms and severe behavioral problems.
When a person with AD or other dementia moves to an
assisted living residence or nursing home, the help provided
by his or her family caregiver usually changes from hands-
on, ADL-types of care to visiting, providing emotional
support to the relative in residential care, interacting with fa-
cility staff, and advocating for appropriate care for the family
member in residential care. However, some family caregivers
continue to help with bathing, dressing, and other ADLs
[139–141]. Admitting a relative to a residential care setting
(such as a nursing home) has mixed effects on the
emotional and psychologicalwell-being of family caregivers.
Some studies suggest that distress remains unchanged or even
increases after a relative is admitted to a residential care facil-
ity, but other studies have found that distress declines
significantly after admission [141,142]. The relationship
between the caregiver and person with dementia may
explain these discrepancies. For example, husbands, wives,
and daughters were significantly more likely to indicate
persistent burden up to 12 months after placement than
other family caregivers, whereas husbands were more
likely than other family caregivers to indicate persistent
depression up to a year after a relative’s admission to
a residential care facility [142].
5.1.4. Duration of caregiving
Caregivers of peoplewithADand other dementias provide
care for a longer time, on average, than do caregivers of older
adults with other conditions. As shown in Fig. 7, 43% of care-
givers of peoplewithADand other dementias provide care for
1 to 4 years compared with 33% of caregivers of peopledementias vs caregivers of other older peoplewho provide help with specific
from the National Alliance for Caregiving and the AARP [137].
Fig. 7. Proportion of Alzheimer’s disease (AD) and dementia caregivers vs caregivers of other older people by duration of caregiving in the United States for the
year 2009. Created from data from the National Alliance for Caregiving and the AARP [137].
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vide care for more than 5 years compared with 28% of care-
givers of people without dementia [137].
5.1.5. Hours of unpaid care and economic value of
caregiving
In 2012, the 15.4 million family members and other
unpaid caregivers of people with AD and other dementias
provided an estimated 17.5 billion hours of unpaid care.
This number represents an average of 21.9 hours of care
per caregiver per week, or 1139 hours of care per caregiver
per year.A16 With this care valued at $12.33/hour,A17 the es-
timated economic value of care provided by family and other
unpaid caregivers of people with dementia was $216.4 bil-
lion in 2012. Table 6 shows the total hours of unpaid care
as well as the value of care provided by family and other un-
paid caregivers for the United States and each state. Unpaid
caregivers of people with AD and other dementias provide
care valued at more than $1 billion in each of 39 states. Un-
paid caregivers in each of the four most populous states—
California, Florida, New York, and Texas—provided care
valued at more than $14 billion.
Some studies suggest that family caregivers provide even
more intensive daily support to people who reach a clinical
threshold of dementia. For example, a recent report from
ADAMS found that family caregivers of people who were
categorized as having dementia spent an average of 9
hours/day providing help to their relatives [136].
5.1.6. Impact of AD caregiving
Caring for a person with AD and other dementias poses
special challenges. For example, people with AD experi-
ence losses in judgment, orientation, and the ability to un-
derstand and communicate effectively. Family caregivers
must often help people with AD manage these issues. The
personality and behavior of a person with AD are affected
as well, and these changes are often among the most chal-
lenging for family caregivers [138]. Individuals with de-
mentia may also require increasing levels of supervision
and personal care as the disease progresses. As these symp-
toms worsen with the progression of a relative’s dementia,the care required of family members can result in family
caregivers’ experiencing increased emotional stress, depres-
sion, impaired immune system response, health impair-
ments, lost wages resulting from disruptions in
employment, and depleted income and finances [143–
148].A15 The intimacy and history of experiences and
memories that are often part of the relationship between
a caregiver and care recipient may also be threatened
from the memory loss, functional impairment, and
psychiatric/behavioral disturbances that can accompany
the progression of AD.
5.1.6.1. Caregiver emotional well-being
Although caregivers report some positive feelings about
caregiving, including family togetherness and the satisfac-
tion of helping others,A15 they also report high levels of
stress during the course of providing care:
 Based on a level of care index that combined the
number of hours of care and the number of ADL tasks
performed by the caregiver, fewer dementia care-
givers in the 2009 NAC/AARP survey were classified
in the lowest level of burden compared with care-
givers of people without dementia (17% vs 31%, re-
spectively) [137].
 Sixty-one percent of family caregivers of people with
AD and other dementias rated the emotional stress of
caregiving as high or very high (Fig. 8).A15
 Most family caregivers report “a good amount” to “a
great deal” of caregiving strain concerning financial is-
sues (56%) and family relationships (53%).A15
 Earlier research in smaller samples found that more
than one-third (39%) of caregivers of people with de-
mentia suffered from depression compared with 17%
of noncaregivers [149,150]. A meta-analysis of re-
search comparing caregivers affirmed this gulf in the
prevalence of depression between caregivers of people
with dementia and noncaregivers [147]. In the
ADAMS sample, 44% of caregivers of people with de-
mentia indicated depressive symptoms, compared with
27% of caregivers of people who had cognitive impair-
ment but no dementia [136].
Table 6
Number of AD/D caregivers, hours of unpaid care, economic value of the


















Alabama 297 338 $4171 $161
Alaska 33 37 $459 $26
Arizona 303 345 $4250 $143
Arkansas 172 196 $2419 $92
California 1528 1740 $21,450 $830
Colorado 231 264 $3250 $121
Connecticut 175 200 $2461 $132
Delaware 51 58 $715 $37
District of
Columbia
26 30 $368 $24
Florida 1015 1156 $14,258 $630
Georgia 495 563 $6944 $235
Hawaii 64 73 $895 $38
Idaho 76 87 $1067 $37
Illinois 584 665 $8202 $343
Indiana 328 373 $4604 $190
Iowa 135 154 $1897 $81
Kansas 149 170 $2099 $88
Kentucky 266 303 $3731 $152
Louisiana 226 258 $3180 $134
Maine 68 77 $951 $50
Maryland 282 321 $3962 $184
Massachusetts 325 370 $4557 $262
Michigan 507 577 $7118 $291
Minnesota 243 277 $3415 $157
Mississippi 203 231 $2854 $115
Missouri 309 351 $4333 $187
Montana 47 54 $663 $27
Nebraska 80 92 $1128 $49
Nevada 135 153 $1889 $67
New Hampshire 64 73 $905 $44
New Jersey 439 500 $6166 $289
New Mexico 105 120 $1480 $61
New York 1003 1142 $14,082 $726
North Carolina 437 497 $6132 $245
North Dakota 28 32 $400 $19
Ohio 589 671 $8267 $361
Oklahoma 214 244 $3004 $121
Oregon 167 191 $2352 $96
Pennsylvania 667 760 $9369 $447
Rhode Island 53 60 $746 $38
South Carolina 287 327 $4031 $157
South Dakota 36 41 $510 $22
Tennessee 414 472 $5815 $229
Texas 1294 1474 $18,174 $665
Utah 137 156 $1918 $60
Vermont 30 34 $416 $20
Virginia 443 504 $6216 $241
Washington 323 368 $4538 $190
West Virginia 108 123 $1520 $72
Wisconsin 189 215 $2656 $120
Wyoming 27 31 $385 $17
U.S. total 15,410 17,548 $216,373 $9121
Abbreviations: AD/D, Alzheimer’s disease and other dementias.
NOTE. Differences between U.S. totals and summing the state numbers
are the result of rounding. Created from data from the 2009 Behavioral
Risk Factor Surveillance System (BRFSS) survey, the U.S. Census Bureau,
the Centers for Medicare and Medicaid Services, the National Alliance for
Caregiving, the AARP, and the U.S. Department of Labor.A14,A16,A17,A18
Fig. 8. Proportion of Alzheimer’s disease and dementia caregivers who
report high or very high emotional and physical stress resulting from care-
giving. Created from data from the Alzheimer’s Association.A15
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likely to indicate stress were women, older, residing
with the care recipient, white or Hispanic, and be-
lieved there was no choice in taking on the role of
caregiver [137].
 When caregivers report being stressed because of the
impaired person’s behavioral symptoms, it increases
the chance that they will place the care recipient in
a nursing home [134,137,151].
 Seventy-seven percent of family caregivers of people
with AD and other dementias said that they somewhat
agree to strongly agree that there is no “right or wrong”
when families decide to place their family member in
a nursing home. Yet, many such caregivers experience
feelings of guilt, emotional upheaval, and difficulties in
adapting to the admission transition (e.g., interacting
with care staff to determine an appropriate care role
for the family member) [139,141,152,153].A15
 Demands of caregiving may intensify as people with
dementia near the end of life. In the year before the per-
son’s death, 59% of caregivers felt they were “on duty”
24 hours a day, and many felt that caregiving during
this time was extremely stressful. One study of end-
of-life care found that 72% of family caregivers said
they experienced relief when the person with AD or
other dementia died [141,154,155].
5.1.6.2. Caregiver physical health
For some caregivers, the demands of caregiving may
cause declines in their own health. Specifically, family care-
givers of people with dementia may experience greater risk
of chronic disease, physiological impairments, increased
health care use, and mortality than those who are not care-
givers [145]. Forty-three percent of caregivers of people
with AD and other dementias reported that the physical im-
pact of caregiving was high to very high (Fig. 8).A15
5.1.6.2.1. General health
Seventy-five percent of caregivers of people with AD and
other dementias reported that they were “somewhat
Alzheimer’s Association / Alzheimer’s & Dementia 9 (2013) 208–245 225concerned” to “very concerned” about maintaining their own
health since becoming a caregiver.A15 Dementia caregivers
weremore likely than noncaregivers to report that their health
was fair or poor [145]. Dementia caregivers were also more
likely than caregivers of other older people to say that care-
giving made their health worse [137,156]. Data from the
2010 BRFSS caregiver survey found that 7% of dementia
caregivers say the greatest difficulty of caregiving is that it
creates or aggravates their own health problems, compared
with 2% of other caregivers [134]. Other studies suggest
that caregiving tasks have the positive effect of keeping older
caregivers more physically active than noncaregivers [157].
5.1.6.2.2. Physiological changes
The chronic stress of caregiving is associated with phys-
iological changes that indicate risk of developing chronic
conditions. For example, a series of recent studies found
that, under certain conditions, some AD caregivers were
more likely to have elevated biomarkers of cardiovascular
disease risk and impaired kidney function risk than those
who were not caregivers [158–163]. Overall, the literature
remains fairly consistent in suggesting that the chronic
stress of dementia care can have potentially negative
influences on caregiver health.
Caregivers of a spouse with AD or other dementias are
more likely than married noncaregivers to have physiologi-
cal changes that may reflect declining physical health,
including high levels of stress hormones [164], reduced im-
mune function [143,165], slow wound healing [166], in-
creased incidence of hypertension [167], coronary heart
disease [168], and impaired endothelial function (the endo-
thelium is the inner lining of the blood vessels). Some of
these changes may be associated with an increased risk of
cardiovascular disease [169].
5.1.6.2.3. Health care use
The physical and emotional impact of dementia caregiv-
ing is estimated to have resulted in $9.1 billion in health care
costs in the United States in 2012.A18 Table 6 shows the
estimated higher health care costs for AD and dementia care-
givers in each state.Fig. 9. Effect of caregiving on work: work-related changes among caregivers of pe
the Alzheimer’s Association.A15Dementia caregivers were more likely to visit the emer-
gency department or be hospitalized during the preceding
6 months if the care recipient was depressed, had low func-
tional status, or had behavioral disturbances than if the care
recipient did not exhibit these symptoms [170].
5.1.6.2.4. Mortality
The health of a person with dementia may also affect the
caregiver’s risk of dying, although studies have reported
mixed findings on this issue. In one study, caregivers of
spouses who were hospitalized and had medical records of
dementia were more likely to die in the following year
than caregivers whose spouses were hospitalized but did
not have dementia, even after accounting for the age of care-
givers [171]. However, other studies have found that care-
givers have lower mortality rates than noncaregivers
[172,173]. One study reported that higher levels of stress
were associated with higher rates of mortality in both
caregivers and noncaregivers [173]. These findings suggest
that it is high stress, not caregiving per se, that increases
the risk of mortality. Such results emphasize that dementia
caregiving is a complex undertaking; simply providing
care to someone with AD or other dementia may not result
consistently in stress or negative health problems for care-
givers. Instead, the stress of dementia caregiving is influ-
enced by a number of other factors, such as dementia
severity, how challenging the caregivers perceive certain as-
pects of care to be, available social support, and caregiver
personality. All these factors are important to consider
when understanding the health impact of caring for a person
with dementia [174].
5.1.6.3. Caregiver employment
Among caregivers of people with AD and other demen-
tias, about 60% reported being employed full- or part-time
[137]. Employed dementia caregivers indicate having to
make major changes to their work schedules because of their
caregiving responsibilities. Sixty-five percent said they had
to go in late, leave early, or take time off, and 20% had to
take a leave of absence. Other work-related changes pertain-
ing to caregiving are summarized in Fig. 9.A15ople with Alzheimer’s disease and other dementias. Created from data from
Alzheimer’s Association / Alzheimer’s & Dementia 9 (2013) 208–2452265.1.7. Interventions that may improve caregiver outcomes
Intervention strategies to support family caregivers of peo-
plewithADhavebeendevelopedand evaluated.The types and
focus of these interventions are summarized in Table 7 [175].
In general, these interventions aim to lessen negative as-
pects of caregiving with the goal of improving health out-
comes of dementia caregivers. Methods used to
accomplish this objective include enhancing caregiver strat-
egies to manage dementia-related symptoms, bolstering re-
sources through enhanced social support, and providing
relief/respite from daily care demands. Desired outcomes
of these interventions include decreased caregiver stress
and depression, and delayed nursing home admission of
the person with dementia.
Characteristics of effective caregiver interventions
include programs that are administered over long periods
of time, interventions that approach dementia care as an
issue for the entire family, and interventions that train
dementia caregivers in the management of behavioral
problems [176–178]. Multidimensional interventions
appear particularly effective. These approaches combine
individual consultation, family sessions and support, and
ongoing assistance to help dementia caregivers manage
changes that occur as the disease progresses. TwoTable 7
Types and focus of caregiver interventions
Type of
Intervention Description
Psychoeducational Includes a structured program that provides
information about the disease, resources, and
services, and about how to expand skills to respond
effectively to symptoms of the disease (i.e.,
cognitive impairment, behavioral symptoms, and
care-related needs). Includes lectures, discussions,
and written materials, and is led by professionals
with specialized training.
Supportive Focuses on building support among participants and
creating a setting in which to discuss problems,
successes, and feelings regarding caregiving.
Group members recognize that others have similar
concerns. Interventions provide opportunities to
exchange ideas and strategies that are most
effective. These groups may be led by
professionals or peers.
Psychotherapy Involves a relationship between the caregiver and
a trained therapy professional. Therapists may
teach such skills as self-monitoring, and
challenging negative thoughts and assumptions;
and help develop problem-solving abilities with
a focus on time management, overload,
management of emotions, and reengagement in
pleasant activities and positive experiences.
Multicomponent Includes various combinations of interventions, such
as psychoeducational, supportive,
psychotherapeutic, and technological approaches.
These interventions are led by skilled
professionals.
NOTE. Created from data from S€orensen and colleagues [175].examples of successful multidimensional interventions are
the New York University Caregiver Intervention [179,180]
and the Resources for Enhancing Alzheimer’s Caregiver
Health (or REACH) II programs [148,175,181–183].
Although less consistent in their demonstrated benefits,
support group strategies and respite services such as adult
day programs may offer encouragement or relief to enhance
caregiver outcomes. The effects of pharmacological therapies
for treating symptoms of dementia (e.g., acetylcholinesterase
inhibitors, memantine, antipsychotics, and antidepressants)
also appear to reduce caregiver stress modestly [184].
Several sources [175,178,179,185–190] recommend
that caregiver services identify “the risk factors and
outcomes unique to each caregiver” [178] when selecting
caregiver interventions. More work is needed, however, in
testing the efficacy of these support programs among dif-
ferent caregiver groups to ensure their benefits for care-
givers across diverse clinical, racial, ethnic,
socioeconomic, and geographic contexts [191].5.2. Paid caregivers5.2.1. Direct-care workers for people with AD and other
dementias
Direct-care workers, such as nurse aides, home health
aides, and personal and home care aides, comprise the ma-
jority of the formal health care delivery system for older
adults (including those with AD and other dementias). In
nursing homes, nursing assistants make up the majority of
staff who work with cognitively impaired residents
[192,193]. Most nursing assistants are women, an
increasing number of whom are diverse in terms of ethnic
or racial background. Nursing assistants help with bathing,
dressing, housekeeping, food preparation, and other
activities.
Direct-care workers have difficult jobs, and they may not
receive the training necessary to provide dementia care
[192,194]. One review found that direct-care workers
received, on average, 75 hours of training that included little
focus on issues specific or pertinent to dementia care [192].
Turnover rates are high among direct-care workers, and
recruitment and retention are persistent challenges [133].
An additional challenge is that, although direct-care workers
are often at the forefront of dementia care delivery in nursing
homes, these staff members are unlikely to receive adequate
dementia training because of insufficient administrative sup-
port. Reviews have shown that staff training programs to
improve the quality of dementia care in nursing homes
have modest, positive benefits [195].
5.2.2. Shortage of geriatric health care professionals in the
United States
Professionals who may receive special training in caring
for older adults include physicians, physician assistants,
nurses, social workers, pharmacists, case workers, and
Table 8
Average annual per-person payments for health care and long-term care
services, Medicare beneficiaries age 65 and older, with and without AD and
other dementias, and by place of residence, in 2012 dollars
Payment
source
Beneficiaries with AD and other










Medicare $20,638 $18,380 $23,792 $7832
Medicaid 10,538 232 24,942 549
Uncompensated 284 408 112 320
HMO 1036 1607 236 1510
Private insurance 2355 2588 2029 1584
Other payer 943 171 2029 149
Out of pocket 9754 3297 18,780 2378
Total* 45,657 26,869 71,917 14,452
Abbreviations: AD, Alzheimer’s disease; HMO, health maintenance or-
ganization.
NOTE. Created from unpublished data from the Medicare Current Bene-
ficiary Survey for 2008 [117].
*Payments from sources do not equal total payments exactly because of
the effect of population weighting. Payments for all beneficiaries with AD
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an additional 3.5 million health care professionals by 2030
just to maintain the current ratio of health care professionals
to the older population [133]. The need for health care pro-
fessionals trained in geriatrics is escalating, but few pro-
viders choose this career path. It is estimated that the
United States has approximately half the number of certified
geriatricians that it currently needs [196]. In 2010, there
were 4278 physicians practicing geriatric medicine in the
United States. An estimated 36,000 geriatricians will be
needed to meet adequately the needs of older adults in the
United States by 2030 [133]. Other health-related
professions also have low numbers of geriatric specialists
relative to the population’s needs. According to the Institute
of Medicine, less than 1% of registered nurses, physician
assistants, and pharmacists identify themselves as specializ-
ing in geriatrics [133]. Similarly, although 73% of social
workers have clients age 55 and older, and between 7.6%
and 9.4% of social workers are employed in long-term
care settings, only 4% have formal certification in geriatric
social work [133].and other dementias include payments for community-dwelling and
facility-dwelling beneficiaries.6. Use and costs of health care, long-term care, and
hospice
As the number of people with AD and other dementias
grows, spending for their care will increase dramatically.
For people with these conditions, aggregate payments for
health care, long-term care, and hospice are projected to
increase from $203 billion in 2013 to $1.2 trillion in 2050
(in 2013 dollars).A19 Medicare and Medicaid cover about
70% of the costs of care. All costs that follow are reported
in 2012 dollars,A20 unless otherwise indicated.Fig. 10. Estimated aggregate costs of care by payer for Americans age 65
years and older with Alzheimer’s disease and other dementias for 2013.
“Other” payment sources include private insurance, health maintenance or-
ganizations, other managed care organizations, and uncompensated care.
Data are in 2013 dollars. Created from data from the application of the
Lewin ModelA19 to data from the Medicare Current Beneficiary Survey
for 2008 [117].6.1. Total payments for health care, long-term care, and
hospice
Table 8 reports the average per-person payments for
health care and long-term care services for Medicare benefi-
ciaries with AD and other dementias. In 2008, total
per-person payments from all sources for health care and
long-term care for Medicare beneficiaries with AD and other
dementias were three times as great as payments for other
Medicare beneficiaries in the same age group ($45,657/per-
son for those with dementia compared with $14,452/person
for those without dementia) [117]. A21
Twenty-nine percent of older individuals with AD and
other dementias who have Medicare also have Medicaid
coverage, compared with 11% of individuals without
dementia [117]. Medicaid pays for nursing home and other
long-term care services for some people with very low
income and low assets, and the high use of these services
by people with dementia translates into high costs for the
Medicaid program. In 2008, average Medicaid payments
per person for Medicare beneficiaries age 65 and older
with AD and other dementias were 19 times as great asaverage Medicaid payments for Medicare beneficiaries
without AD and other dementias ($10,538/person for
individuals with dementia compared with $549/person for
individuals without dementia; Table 8) [117].
Total payments for 2013 are estimated at $203 billion,
including $142 billion for Medicare andMedicaid combined
in 2013 dollars (Fig. 10). These figures are derived from
a model developed by The Lewin Group using data from
the Medicare Current Beneficiary Survey and The Lewin
Group’s Long-Term Care Financing Model.A19
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People with AD and other dementias have more than
three times as many hospital stays per year as other older
people [117]. Moreover, the use of health care services for
people with other serious medical conditions is strongly
affected by the presence or absence of dementia. In particu-
lar, people with coronary heart disease, diabetes mellitus,
chronic kidney disease, chronic obstructive pulmonary dis-
ease, stroke, or cancer who also have AD and other demen-
tias have higher use and costs of health care services than
people with these medical conditions but no coexisting
dementia.
6.2.1. Use of health care services
Older people with AD and other dementias have more
hospital stays, skilled nursing facility stays, and home health
care visits than other older people:
 Hospital: In 2008, there were 780 hospital stays per
1000 Medicare beneficiaries age 65 and older with
AD and other dementias compared with 234 hospital
stays per 1000 Medicare beneficiaries age 65 and older
without these conditions [117]. The most common rea-
sons for hospitalization of people with AD include syn-
cope, fall and trauma (26%), ischemic heart disease
(17%), and gastrointestinal disease (9%; Fig. 11)
[197].
 Skilled nursing facility: Skilled nursing facilities pro-
vide direct medical care that is performed or super-
vised by registered nurses, such as giving intravenous
fluids, changing dressings, and administering tube
feedings [198]. In 2008, there were 349 skilled nursing
facility stays per 1000 beneficiaries with AD and other
dementias compared with 39 stays per 1000 beneficia-
ries for people without these conditions [117].
 Home health care: In 2008, 23% of Medicare benefi-
ciaries age 65 and older with AD and other dementias
had at least one home health visit during the year, com-Fig. 11. Reasons for hospitalization of peoplewith Alzheimer’s disease (AD): perc
individuals with a clinical diagnosis of probable or possible AD were used to calc
reasons. Created from data from Rudolph and colleagues [197].pared with 10% of Medicare beneficiaries age 65 and
older without AD and other dementias [102].
6.2.2. Costs of health care services
With the exception of prescription medications, average
per-person payments for all other health care services (hos-
pital, physician and other medical provider, nursing home,
skilled nursing facility, and home health care) were higher
for Medicare beneficiaries with AD and other dementias
than for other Medicare beneficiaries in the same age group
(Table 9) [117]. The fact that only payments for prescription
drugs are less for those with AD and other dementias under-
scores the lack of effective treatments available to those with
dementia.
6.2.3. Impact of coexisting medical conditions on use and
costs of health care services
Medicare beneficiaries with AD and other dementias are
more likely than thosewithout dementia to have other chronic
conditions [102]. Table 10 reports the proportion of people
with AD and other dementias who have certain coexisting
medical conditions. In 2009, 30% of Medicare beneficiaries
age 65 and older with dementia also had coronary heart dis-
ease; 29%, diabetes; 22%, congestive heart failure; 17%,
chronic kidney disease; and 17%, chronic obstructive pulmo-
narydisease [102]. PeoplewithADandother dementias, in ad-
dition to other serious coexistingmedical conditions, aremore
likely to be hospitalized than people with the same coexisting
medical conditions but without dementia (Fig. 12) [102].
Similarly, Medicare beneficiaries who have AD and other
dementias in addition to another serious coexisting medical
condition have higher average per-person payments for most
health care services than Medicare beneficiaries who have
the same medical conditions without dementia. Table 11
shows the average per-person total Medicare payments and
average per-person Medicare payments for hospital, physi-
cian, skilled nursing facility, home health, and hospice
care for beneficiaries with other serious medical conditionsentage of hospitalized people by admitting diagnosis. All hospitalizations for
ulate percentages. The remaining 37% of hospitalizations were from other
Table 9
Average annual per-person payments for health care services provided to






AD and other dementias
Inpatient hospital $10,293 $4138
Medical provider* 6095 4041
Skilled nursing facility 3955 460
Nursing home 18,353 816
Hospice 1821 178
Home health 1460 471
Prescribed medicationsy 2787 2840
Abbreviation: AD, Alzheimer’s disease.
NOTE. Created from unpublished data from the Medicare Current Bene-
ficiary Survey for 2008 [117] in 2012 dollars.
*Includes physicians, other medical provider and laboratory services, and
medical equipment and supplies.
yInformation on payments for prescription drugs is only available for peo-
ple who were living in the community—that is, not in a nursing home or
assisted living facility.
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Medicare beneficiaries with a serious medical condition and
dementia had higher average per-person payments than
Medicare beneficiaries with the same medical condition
but without dementia, with the exceptions of hospital care
and total Medicare payments for beneficiaries with conges-
tive heart failure.6.3. Use and costs of long-term care services
An estimated 60% to 70% of older adults with AD and
other dementias live in the community compared with
98% of older adults without AD and other dementias
[117,199]. Of those with dementia who live in the
community, 75% live with someone and the remaining
25% live alone [117]. People with AD and other dementias
generally receive more care from family members and other
unpaid caregivers as their disease progresses. Many people
with dementia also receive paid services at home; in adult
day centers, assisted living facilities, or nursing homes; orTable 10
Specific coexisting medical conditions among Medicare beneficiaries age
65 and older with AD and other dementias, 2009
Coexisting condition
Percentage of people with AD
and other dementias who also
had a coexisting medical
condition
Coronary heart disease 30%
Diabetes mellitus 29%
Congestive heart failure 22%
Chronic kidney disease 17%
Chronic obstructive pulmonary disease 17%
Stroke 14%
Cancer 9%
Abbreviation: AD, Alzheimer’s disease.
NOTE. Created from unpublished data from the National 20% Sample
Medicare Fee-for-Service Beneficiaries for 2009 [102].in more than one of these settings at different times in the of-
ten long course of their illness. Given the high average costs
of these services (adult day services, $70 per day [199]; as-
sisted living, $42,600 per year [199]; and nursing home care,
$81,030 to $90,520/year [199]), individuals often deplete
their income and assets, and eventually qualify forMedicaid.
Medicaid is the only public program that covers the long
nursing home stays that most people with dementia require
in the late stages of their illnesses.6.3.1. Use of long-term care services by setting
Most people with AD and other dementias who live at
home receive unpaid help from family members and friends,
but some also receive paid home and community-based ser-
vices, such as personal care and adult daycare. A study of
older people who needed help to perform daily activities
such as dressing, bathing, shopping, and managing money
found that those who also had cognitive impairment were
more than twice as likely as thosewho did not have cognitive
impairment to receive paid home care [200]. In addition,
those who had cognitive impairment and received paid ser-
vices used almost twice as many hours of care monthly as
those who did not have cognitive impairment [200].
People with AD and other dementias make up a large pro-
portion of all elderly people who receive nonmedical home
care, adult day services, assisted living and residential
care, nursing home care, and AD special care units:
 Home care: According to state home care programs in
Connecticut, Florida, and Michigan, more than one-
third (about 37%) of older people who receive primar-
ily nonmedical home care services, such as personal
care and homemaker services, have cognitive impair-
ment consistent with dementia [201–203].
 Adult day services: At least half of elderly attendees at
adult day centers have dementia [204,205].
 Assisted living and residential care: Forty-two percent
of residents in assisted living and residential care facil-
ities had AD and other dementias in 2010 [206].
 Nursing home care: Of all nursing home residents,
68% have some degree of cognitive impairment; 27%
have very mild to mild cognitive impairment and
41% have moderate to severe cognitive impairment
(Table 12) [207]. Of all Medicare beneficiaries age
65 and older living in a nursing home, 64% have AD
and other dementias [117].
 AD special care units: An AD special care unit is a sep-
arate unit in a nursing home that has special services
for individuals with AD and other dementias. Nursing
homes had a total of 79,937 beds in AD special care
units in June 2012 [208]. These AD special care unit
beds accounted for 72% of all special care unit beds
and 5% of all nursing home beds at that time. The num-
ber of nursing home beds in AD special care units in-
creased during the 1980s but has decreased since
2004, when there were 93,763 beds in such units [209].
Fig. 12. Hospital stays per 1000 beneficiaries aged 65 years and older with specified coexisting medical conditions, with and without Alzheimer’s disease (AD)
and other dementias, in 2009. Created from unpublished tabulations based on data from the National 20% Sample Medicare Fee-for-Service Beneficiaries for
2009 [102].
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long-term acute hospital care services, there have been
a number of restrictions on adding new facilities and increas-
ing the number of beds in existing facilities. In addition, the
Medicare, Medicaid, and State Children’s Health Insurance
Program Extension Act of 2007 issued a 3-year moratorium
on the designation of new long-term care hospitals and in-
creases in Medicare–certified beds for existing long-term
care hospitals [210]. Long-term care hospitals are acuteTable 11
Average annual per-person payments by type of service and coexisting medical con
other dementias for 2009, in 2012 dollars*
Medical condition
by AD/D status
Average per-person Medicare payments
Total Medicare payments Hospital care Physician c
Coronary heart disease
With AD/D 27,286 10,312 1718
Without AD/D 16,924 7410 1314
Diabetes mellitus
With AD/D 26,627 9813 1608
Without AD/D 14,718 6048 1132
Congestive heart failure
With AD/D 26,149 11,712 1773
Without AD/D 30,034 11,991 1772
Chronic kidney disease
With AD/D 32,190 12,927 1902
Without AD/D 24,767 10,834 1665
Chronic obstructive pulmonary disease
With AD/D 29,660 11,521 1811
Without AD/D 20,260 9029 1488
Stroke
With AD/D 27,774 10,160 1669
Without AD/D 19,940 7875 1419
Cancer
With AD/D 25,559 9135 1567
Without AD/D 16,727 6198 1202
Abbreviation: AD/D, Alzheimer’s disease/dementia.
NOTE. Created from unpublished data from the National 20% Sample Medica
*This table does not include payments for all kinds of Medicare services; as a re
sum to the total per-person Medicare payments.care hospitals that serve patients who have long-term acute
medical care needs, with average lengths of hospital stay
of more than 25 days [211]. Patients are often transferred
from the intensive care units of acute care hospitals to
long-term care hospitals for medical care related to rehabil-
itation services, respiratory therapy, and pain management.
This moratorium was issued in response to the need for
Medicare to develop criteria for patients admitted to long-
term care hospitals with Medicare coverage as a result ofdition for Medicare beneficiaries age 65 and older, with and without AD and















re Fee-for-Service Beneficiaries for 2009 [102].
sult, the average per-person payments for specific Medicare services do not
Table 12




Percentage of residents at each






Alabama 52,312 29 27 44
Alaska 1328 32 29 39
Arizona 41,703 48 24 28
Arkansas 33,723 23 29 48
California 259,778 36 26 38
Colorado 40,681 33 29 39
Connecticut 63,252 39 25 36
Delaware 9842 35 28 37
District of
Columbia
5448 36 26 38
Florida 212,553 41 23 36
Georgia 68,186 16 23 61
Hawaii 8574 25 22 53
Idaho 12,558 34 26 40
Illinois 169,385 29 32 39
Indiana 84,063 37 29 34
Iowa 48,471 22 31 47
Kansas 35,871 24 31 45
Kentucky 50,942 32 24 44
Louisiana 43,523 25 26 49
Maine 18,802 37 25 38
Maryland 65,917 40 23 37
Massachusetts 103,135 36 23 41
Michigan 104,790 33 26 41
Minnesota 70,474 30 30 40
Mississippi 29,306 23 29 48
Missouri 78,350 31 31 39
Montana 10,795 24 30 46
Nebraska 27,007 28 30 42
Nevada 13,630 43 26 31
New Hampshire 15,831 34 24 42
New Jersey 120,300 42 24 34
New Mexico 13,423 32 28 40
New York 232,754 35 25 40
North Carolina 89,429 35 24 42
North Dakota 10,609 22 31 47
Ohio 190,576 30 27 42
Oklahoma 37,263 29 31 40
Oregon 27,099 37 29 34
Pennsylvania 189,524 33 28 40
Rhode Island 17,388 32 28 40
South Carolina 39,616 29 23 48
South Dakota 11,347 20 31 49
Tennessee 71,723 26 27 48
Texas 192,450 19 30 51
Utah 17,933 38 27 34
Vermont 7106 31 24 45
Virginia 73,685 34 26 39
Washington 57,335 33 28 39
West Virginia 21,815 37 21 42
Wisconsin 73,272 35 27 38
Wyoming 4792 19 28 54
U.S. total 3,279,669 32 27 41
NOTE. Created from data from the U.S. Department of Health and Hu-
man Services [207].
*These figures include all individuals who spent any time in a nursing
home in 2009.
yPercentages for each state may not sum to 100 because of rounding.
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and beds. The moratorium expired on December 28, 2012
[210,212]. In 2011, certificate-of-need programs were in
place to regulate nursing home beds in 37 states, and a num-
ber of these states had implemented a certificate-of-need
moratorium on the number of beds and/or facilities [213].
6.3.2. Costs of long-term care services
Costs are high for care provided at home or in an adult
day center, assisted living facility, or nursing home. The fol-
lowing estimates are for all users of these services. The only
exception is the cost of AD special care units in nursing
homes, which only applies to the people with AD and other
dementias who are in these units.
 Home care: In 2011, the average cost for a paid non-
medical home health aide was $21/hour, or $168 for
an 8-hour day [199].
 Adult day centers: In 2011, the average cost of adult
day services was $70/day. Ninety-five percent of adult
day centers provided care for peoplewith AD and other
dementias, and 2% of these centers charged an addi-
tional fee for these clients [199].
 Assisted living: In 2011, the average cost for basic ser-
vices in an assisted living facility was $3550/month, or
$42,600/year. Seventy-two percent of assisted living
facilities provided care to people with AD and other
dementias, and 52% had a specific unit for people
with AD and other dementias. In facilities that charged
a different rate for individuals with dementia, the aver-
age rate was $4807/month, or $57,684/year, for this
care [199].
 Nursing homes: In 2011, the average cost for a private
room in a nursing homewas $248/day, or $90,520/year.
The average cost of a semiprivate room in a nursing
home was $222/day, or $81,030/year. Approximately
80% of nursing homes that provide care for people
with AD charge the same rate, regardless of whether
the individual has AD. In the few nursing homes that
charged a different rate, the average cost for a private
room for an individual with AD was $13 higher
($261/day, or $95,265/year) and the average cost for
a semiprivate room was $8 higher ($230/day, or
$83,950/year) [199]. Fifty-five percent of nursing
homes that provide care for people with AD other de-
mentias had separate AD special care units [199].
6.3.3. Affordability of long-term care services
Few individuals with AD and other dementias have suf-
ficient long-term care insurance or can afford to pay out of
pocket for long-term care services for as long as the services
are needed.
 Income and asset data are not available for people with
AD and other dementias specifically, but 50% ofMedi-
care beneficiaries had incomes of $22,276 or less, and
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dollars). Two hundred percent of the U.S. Census Bu-
reau’s poverty threshold was $21,576 for one person
age 65 and older, and $27,192 for a family of two,
with the head of household age 65 and older [214,215].
 Fifty percent of Medicare beneficiaries had retirement
accounts of $2203 or less, 50% had financial assets of
$31,849 or less, and 50% had total savings of $55,516
or less, equivalent to less than 1 year of nursing home
care in 2010 (in 2012 dollars) [214].6.3.4. Long-term care insurance
In 2010, about 7.3 million people had long-term care in-
surance policies [216]. Private health and long-term care
insurance policies funded only about 7% of total long-term
care spending in 2009, representing $18.4 billion of the
$263 billion (in 2012 dollars) in long-term care spending
[217]. The private long-term care insurance market has de-
creased substantially since 2010, however, with five major
insurance carriers either exiting the market or substantially
increasing premiums, making policies unaffordable for
many individuals [218].
6.3.5. Medicaid costs
Medicaid covers nursing home care and long-term care
services in the community for individuals whomeet program
requirements for level of care, income, and assets. To receive
coverage, beneficiaries must have low incomes. Most nurs-
ing home residents who qualify for Medicaid must spend
all their Social Security income and any other monthly in-
come, except for a very small personal needs allowance, to
pay for nursing home care. Medicaid only makes up the dif-
ference if the nursing home resident cannot pay the full cost
of care or has a financially dependent spouse.
Federal and state governments share in managing and
funding the program, and states differ greatly in the services
covered by their Medicaid programs. Medicaid plays a criti-
cal role for people with dementia who can no longer afford to
pay for long-term care expenses on their own. In 2008, 58%
of Medicaid spending on long-term care was allocated to in-
stitutional care, and the remaining 42% was allocated to
home and community-based services [217].
Total Medicaid spending for people with AD and other
dementias is projected to be $35 billion in 2013.A19 About
half of all Medicaid beneficiaries with AD and other demen-
tias are nursing home residents, and the rest live in the com-
munity [219]. Among nursing home residents with AD and
other dementias, 51% rely on Medicaid to help pay for their
nursing home care [219].
In 2008, total per-person Medicaid payments for Medi-
care beneficiaries age 65 and older with AD and other de-
mentias were 19 times as great as Medicaid payments for
other Medicare beneficiaries. Much of the difference in
payments for beneficiaries with AD and other dementias
is a result of the costs associated with long-term care (nurs-ing homes and other residential care facilities, such as as-
sisted living facilities) and the greater percentage of people
with dementia who are eligible for Medicaid. Medicaid
paid $24,942/person for Medicare beneficiaries with AD
and other dementias living in a long-term care facility com-
pared with $232 for those with the diagnosis living in the
community, and $549 for those without the diagnosis
(Table 8) [117].6.4. Out-of-pocket costs for health care and long-term
care services
Despite other sources of financial assistance, individuals
with AD and other dementias still incur high out-of-pocket
costs. These costs are for Medicare and other health insur-
ance premiums and for deductibles, copayments, and ser-
vices not covered by Medicare, Medicaid, or additional
sources of support.
In 2008, Medicare beneficiaries age 65 and older with
AD and other dementias paid $9754 out of pocket, on av-
erage, for health care and long-term care services not cov-
ered by other sources (Table 8) [117]. Average per-person
out-of-pocket payments were highest ($3297 per person)
for individuals living in nursing homes and assisted living
facilities, and were almost six times as great as the average
per-person payments for individuals with AD and other de-
mentias living in the community [117]. In 2013, out-of-
pocket spending for individuals with AD and other
dementias is expected to total an estimated $34 billion
(Fig. 10).A19
Before implementation of the Medicare Part D Prescrip-
tion Drug Benefit in 2006, out-of-pocket expenses were in-
creasing annually for Medicare beneficiaries [220]. In
2003, out-of-pocket costs for prescription medications
accounted for about one-quarter of total out-of-pocket costs
for all Medicare beneficiaries age 65 and older [221]. The
Medicare Part D Prescription Drug Benefit has helped to re-
duce out-of-pocket costs for prescription drugs for many
Medicare beneficiaries, including beneficiaries with AD
and other dementias [222]. Sixty percent of all Medicare
beneficiaries were enrolled in a Medicare Part D plan in
2011, and the average monthly premium for Medicare Part
D was $39 (range, $15–$132) [222]. As noted earlier, how-
ever, the most expensive component of out-of-pocket costs
for people with AD and other dementias is nursing home
and other residential care.6.5. Use and costs of hospice care
Hospices provide medical care, pain management, and
emotional and spiritual support for people who are dying, in-
cluding people with AD and other dementias. Hospices also
provide emotional and spiritual support and bereavement
services for families of people who are dying. The main pur-
pose of hospice care is to allow individuals to die with dig-
nity, without pain and other distressing symptoms that often
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care in their homes, assisted living residences, or nursing
homes. Medicare is the primary source of payment for hos-
pice care, but private insurance, Medicaid, and other sources
also pay for hospice care.
In 2009, 6% of all people admitted to hospices in the
United States had a primary hospice diagnosis of AD
(61,146 people) [223]. An additional 11% of all people ad-
mitted to hospices in the United States had a primary hospice
diagnosis of non-AD dementia (119,872 people) [223]. Hos-
pice length of stay has increased during the past decade. The
average length of stay for hospice beneficiaries with a pri-
mary hospice diagnosis of AD increased from 67 days in
1998 to 106 days in 2009 [223]. The average length of stay
for hospice beneficiaries with a primary diagnosis of non-
AD dementia increased from 57 days in 1998 to 92 days in
2009 [223]. Average per-person hospice care payments
across all beneficiaries with AD and other dementias were
10 times as great as average per-person payments for all other
Medicare beneficiaries ($1821/person compared with $178/
person) [117].6.6. Projections for the future
Total payments for health care, long-term care, and hos-
pice for people with AD and other dementias are projected
to increase from $203 billion in 2013 to $1.2 trillion in
2050 (in 2013 dollars). This dramatic rise includes a six-
fold increase in government spending under Medicare
and Medicaid and a five-fold increase in out-of-pocket
spending.A19Fig. 13. Travel times between caregivers and care recipients for caregivers
of peoplewho haveAlzheimer’s disease or a related condition. Created from
data from the National Alliance for Caregiving and the AARP [137].7. Special report: Long-distance caregivers
This special report describes the experiences and needs
of a specific type of caregiver: long-distance caregivers—
those who care for a loved one who lives far away. It de-
scribes the characteristics of long-distance caregivers, their
needs, the barriers they encounter, how the caregiving sit-
uation affects them, and efforts that have been made to al-
leviate the caregiving burden they experience. These issues
have received little attention but are the source of increas-
ing concern.
Much of what is known about long-distance caregivers
comes from studies in which the care recipient was an
older person who needed assistance to perform daily activ-
ities because of cognitive or physical impairments. Most
studies were not exclusive to caregivers for someone
with dementia. Nevertheless, in key studies, about 30%
of caregivers reported that the care recipient had AD or
a related condition [224]. Therefore, it is reasonable to ex-
pect that the results of those key studies apply to care-
givers for people with dementia. In some cases, findings
specific to caregivers of people with AD and other demen-
tias are available, and the findings have been included in
this special report.7.1. Definition and prevalence
Studies of long-distance caregivers have differed with
respect to how they define long distance, but a common
definition is one in which the caregiver lives at least 1
or 2 hours away from the care recipient. A 2009 report
from the NAC/AARP [224] compiled information from
1480 caregivers of adults age 18 or older who needed as-
sistance with self-care in the United States. In that report,
9% of caregivers lived 2 or more hours away from the care
recipient and 4% lived 1 to 2 hours away. The remainder
lived less than 1 hour away.
A subanalysis of the NAC/AARP study was performed in
which caregivers were included only if they provided care
for someone 50 years or older who had AD or a related con-
dition. Travel times between those 404 caregivers and their
care recipients are shown in Fig. 13. Nine percent of care-
givers lived 2 hours or more away from the care recipient,
and 6% lived 1 to 2 hours away [137].
On the basis of these findings and the estimate that more
than 15.4 million people in the United States are caregivers
for someone who has AD or other dementia, we estimate
that about 2.3 million of those caregivers live at least 1
hour away from the care recipient. As discussed next, the
types and amount of care these individuals provide vary
greatly.
7.2. Factors influencing geographic separation
As noted in Section 5, most caregivers for people with de-
mentia are relatives of the care recipient. In the subanalysis
of the 2009 NAC/AARP survey, 79% of caregivers for peo-
plewith dementia were caring for their parent, parent-in-law,
grandparent, or grandparent-in-law [137].
Because so many caregivers are a descendant (or
descendant-in-law) of the care recipient, it is worthwhile ex-
ploring the factors that influence geographic separation
between the places of residence of children and their parents.
Several studies have done so [225–227].
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are as follows [225–227]:
 Education levels of parents and children: When par-
ents or their adult children have many years of formal
education, they tend to live farther apart than thosewho
have fewer years of formal education.
 Number of children: Parents who have many adult chil-
dren are more likely to have one child who lives nearby
than parents who have fewer children.
Other factors affecting geographic separation of parents
and children include the following [225–227]:
 Age: Young adult children tend to live closer to their
parents than middle-age children. Parents older than
80 years tend to live closer to their children than par-
ents younger than 80.
 Income: Children with higher incomes tend to live
farther from their parents than children with lower
incomes.
 Children’s family size: Children with large families of
their own tend to live farther from their parents than
children who have small families.
 Geography: Parents who live in rural areas tend to live
farther from their children than parents who live in ur-
ban areas. Children or parents who live in the western
United States tend to live farther from each other than
those who live in the eastern part of the country.
 Geographic mobility: Parents or children who have an
extensive history of geographic mobility tend to live
farther from each other than those who have less his-
tory of geographic mobility.
The gender of adult children does not strongly influence
geographic separation from their parents, even though
daughters are more likely to be caregivers than sons.
The cited studies were not restricted to children who
were caregivers. However, in at least one study the health
and disability levels of parents did not strongly influence
geographic separation between them and their adult chil-
dren [226]. Therefore, it is reasonable to expect that these
same factors influence geographic separation when adult
children are caregivers for their parents. Indeed, small stud-
ies specific to caregivers have found that long-distance
caregivers, on average, are more educated, more affluent,
and more likely to be married than local caregivers
[137,228–231].7.3. Roles
Caregivers for people with dementia perform a variety of
caregiving tasks, and each caregiving situation is unique. In
some studies, unpaid caregivers are categorized into two
groups: primary caregivers and secondary caregivers. In
most of the studies cited here, secondary caregivers are those
who identified themselves as such—that is, they recognized
that another person was the primary caregiver.Primary caregivers of people who have dementia are
more likely than secondary caregivers to help with essential
activities such as dressing, personal hygiene, feeding, move-
ment, and toileting (ADLs). Primary caregivers may also
help with tasks that are less essential for basic functioning
but that help the care recipient live independently; such tasks
include doing housework, managing medications, shopping,
managing money, and providing transportation (instrumen-
tal activities of daily living [IADLs]). Secondary caregivers
are more likely to help with IADLs than ADLs.
In a nationwide survey conducted in 2004 by the MetLife
Mature Market Institute, 23% of long-distance caregivers re-
ported that they were the primary or only caregiver for their
care recipient [228]. In theNAC/AARPsurveys, the percentage
of long-distance caregivers who identified themselves as the
primary caregiver has varied from 11% (2004) to 35% (2009)
[137,230]. Another study of caregivers for people with
dementia in the Los Angeles area found that 19% of long-
distance caregivers considered themselves the primary care-
giver, whereas 65%of local caregivers did so [232]. From these
studies, we estimate that, among long-distance caregivers for
people with dementia, about one in five is a primary caregiver.
Despite the fact that most long-distance caregivers con-
sider themselves secondary caregivers, the MetLife study
[233] found that:
 72% of long-distance caregivers helped the care recip-
ient perform IADLs
 Long-distance caregivers spent an average of 3.4
hours/week arranging services for the care recipient
and another 4 hours/week checking on the care recipi-
ent or monitoring care
 Almost 40% of long-distance caregivers reported that
they helped the care recipient perform ADLs
 On average, long-distance caregivers spent about 22
hours/month helping with IADLs and about 12
hours/month helping with ADLs7.4. Unique challenges
Long-distance caregivers who are the primary caregiver
have the same needs as local primary caregivers, but long-
distance caregivers have the added burden of having to travel
more than an hour to perform most of their caregiving tasks
[232]. Predictably, long-distance caregivers are more likely
than local caregivers to report distance as a barrier to per-
forming their caregiving tasks [231,233].
7.4.1. Coordinating care
Long-distance caregivers, especially those who are sec-
ondary caregivers, frequently assume the role of coordina-
tors of care, working to assist the primary caregiver by
finding, coordinating, and monitoring the recipient’s formal
care and social services [232,234]. Long-distance caregivers
who are primary caregivers may have to take on multiple
roles, providing direct care by helping with ADLs and
IADLs as well as coordinating formal health care and social
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givers often report difficulties in finding services available
in the care recipient’s community and in monitoring service
providers [231]. These tasks can be especially difficult when
the care recipient lives in a rural area.
7.4.2. Assessing the care recipient’s condition and needs
Long-distance caregivers also reported greater difficulty
than local caregivers in obtaining information about the
care recipient [231,232]. Specifically, many long-distance
caregivers report that care recipients either downplay or
exaggerate their condition and needs. As a consequence,
long-distance caregivers may be less able to gauge the care
recipient’s needs [235]. Similarly, long-distance caregivers
have difficulty obtaining accurate information about the re-
cipient’s condition from local caregivers or neighbors.
7.4.3. Communicating with health care providers
Long-distance caregivers may not be available to accom-
pany the care recipient to health care visits, especially when
those visits are unexpected. Furthermore, long-distance
caregivers often find it more difficult than local caregivers
to communicatewith health care providers, whomay assume
that the long-distance caregiver is not an important contact
or is less involved in caregiving. These barriers make it dif-
ficult for long-distance caregivers to acquire accurate infor-
mation about the care recipient’s health status, in turn
making it difficult for these caregivers to assist in making
health care decisions [232,234].
7.4.4. Family strain and disagreements with siblings
Although many of the effects of caregiving are common
to long-distance caregivers and local caregivers, long-
distance caregivers report higher rates of family disagree-
ment [232]. Sources of these problems can vary, but often
include disagreements with siblings about caregiving deci-
sions, and resentment from local caregivers that the long-
distance caregivers are not more helpful [231,232,236].
7.4.5. Psychological distress
In some studies, long-distance caregivers reported higher
rates of psychological distress than local caregivers, even
though local caregivers were more likely to feel over-
whelmed by their caregiving responsibilities [232]. Psycho-
logical distress among long-distance caregivers may arise
from difficulties in ascertaining the care recipient’s condi-
tion and needs, and the fact that long-distance caregivers
are frequently asked to help during acute crises [235].
Some long-distance caregivers may also experience feelings
of regret or remorse resulting from self-assessments that dis-
tance has restricted their caregiving capacity [237].
7.4.6. Employment
About 60% of caregivers for people with dementia are
employed either part-time or full-time [137], and long-
distance caregivers have similar rates of employment[228,237]. Many caregivers miss work and use vacation
or sick days for caregiving. Long-distance caregivers ex-
perience even greater disruptions in their employment
because of the time required to travel to where the care re-
cipient lives [228,232,233].
7.4.7. Financial burden
Given that local caregivers are muchmore likely to be pri-
mary caregivers than long-distance caregivers [137], it is not
surprising that local caregivers provide significantly more
hours of care on average than long-distance caregivers
[232]. Thus, the uncompensated economic value of care pro-
vided by local caregivers is likely greatly to exceed that of
long-distance caregivers. Nevertheless, long-distance care-
givers have significantly higher annual out-of-pocket ex-
penses for care-related costs than local caregivers
[228,238]. In one nationwide survey published in 2007,
long-distance caregivers had annual out-of-pocket expenses
of $9654 compared with $5055 for local caregivers (in 2012
dollars) [238].A20 These expenses included the costs of travel
as well as telephone bills, payment for hired help, and other
expenses associated with long-distance caregiving [238].7.5. Interventions7.5.1. Support for long-distance caregivers
With the growth of the Web, an increasing number of on-
line and computer-aided programs have been developed to
provide assistance to long-distance caregivers. Whether
a program is implemented online, via telephone, or in per-
son, it should reflect the range of support and information
needed by long-distance caregivers, such as
 Access to a professional family consultant who can act
as a liaison between care recipients and long-distance
care providers, and who can help alleviate family dis-
agreements
 Access to print or Web-based elder care resource
guides for the area in which the care recipient lives
 Access to information about elder care attorneys and fi-
nancial planners in the area in which the care recipient
lives
 For both long-distance and other caregivers, assistance
in developing a comprehensive safety plan for the care
recipient that can be accessed and implemented by
both local and long-distance caregivers
 Help with caring for an individual who lives alone7.5.2. Technology
Several caregiving advocacy organizations have issued
calls to use technology to assist long-distance caregivers.
The National Research Council of the U.S. National Acad-
emies convened the Workshop on Technology for Adaptive
Aging in 2003 and outlined research priorities for the de-
velopment of technological devices to assist older adults,
Alzheimer’s Association / Alzheimer’s & Dementia 9 (2013) 208–245236including those with cognitive or physical impairments
[239].
The Workshop report identified core technologies in var-
ious stages of development and how they could help aging
people remain independent, as well as help their caregivers
monitor the care recipient, and provide care and assistance
when needed. Such technologies include wireless broadband
networks to connect care recipients and caregivers, biosen-
sors and diagnostic tools, activity sensors, information pro-
cessing systems to detect changes in health status based on
sensor input, displays and actuators to assist in using appli-
ances and home controls, artificial intelligence devices and
systems that act as personal assistants and coaches, adaptive
interfaces that allow impaired people to perform household
tasks, and other devices and tools. Technological innova-
tions may offer the potential to increase the connectedness
of caregivers and care recipients and may alleviate some
of the burden of caregiving, including the burden of long-
distance caregiving [233,240–243]. Additional research is
needed on the use of technologies to assist long-distance
caregivers.7.6. Trends
As described in Section 3, the number and percentage of
Americans who have AD and other dementias are expected
to increase dramatically in coming decades. Commensurate
with this increase in prevalence are expected increases in the
number and percentage of Americans who are caregivers for
older people who have dementia or other disabilities [133].
Some have predicted that increases in geographic mobil-
ity in the United States will lead to even greater increases in
the percentage of caregivers who live far away from their
care recipient [231]. However, there is not widespread agree-
ment that geographic mobility has been increasing. An ex-
tensive analysis of long-term trends in geographic mobility
in the United States concluded that geographic mobility
rates actually declined between the 1950s and early 2000s
among all age groups [244].
Studies attempting to determine the percentage of care-
givers who are long-distance caregivers have not shown
a consistent increase. Two studies showed modest increases
during the 1980s and 1990s [245,246], but another study
found a modest decrease in recent years (2004–2009)
[224]. However, even if the percentage of long-distance
caregivers is not increasing, their absolute number is likely
to increase along with the number of all caregivers required
to care for increasing numbers of older people who have dis-
abilities, including AD and other dementias.7.7. Conclusions
About 2.3 million people in the United States are care-
givers for a person with AD or other dementia who lives at
least 1 hour away. Although most of those long-distance
caregivers are secondary caregivers, about one in five is a pri-mary caregiver, about seven in 10 help the care recipient
with IADLs, and about four in 10 help with ADLs. Although
long-distance caregivers may spend less time helping the
care recipient than local caregivers, long-distance caregivers
have greater out-of-pocket expenses on average, experience
greater challenges assessing the care recipient’s condition
and needs, report more difficulty communicating with health
care providers, and often experience higher levels of psycho-
logical distress and family discord arising from their care-
giving roles. Thus, support programs tailored to the needs
of long-distance caregivers are needed to address the partic-
ular challenges they encounter.
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A1Number of Americans age 65 and older with AD for
2013: The number 5million is from published prevalence es-
timates based on incidence data from the Chicago Health
and Aging Project (CHAP) and population estimates from
the 2010 U.S. Census [83]. The estimates of Alzheimer’s
prevalence in the United States reported in previous Facts
and Figures reports come from an older analysis using the
same methods but older data from CHAP and data from
the 2000 U.S. Census [108].
A2Proportion of Americans age 65 and older with AD:
The 11% is calculated by dividing the estimated number
of people age 65 and older with AD (5 million) by the
U.S. population age 65 and older in 2013, as projected by
the U.S. Census Bureau (44.2 million), which equals 11%.
Eleven percent is the same as one in nine.
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ages for each age group are based on the estimated
200,000 younger than 65 years, plus the estimated numbers
(in millions) for people age 65 to 74 years (0.7), 75 to 84
years (2.3), and 851 years (2.0) based on prevalence esti-
mates for each age group and incidence data from the Chi-
cago Health and Aging Project [83]. Percentages do not
total 100 due to rounding.
A4Differences between CHAP and ADAMS estimates for
AD prevalence: The Aging, Demographics, and Memory
Study (ADAMS) estimates the prevalence of AD to be less
than does the Chicago Health and Aging Project (CHAP),
at 2.3 million Americans age 71 years and older in 2002
[85]. Note that the CHAP estimates referred to in this end
note are from an earlier study using 2000 U.S. Census data
[108]. At a 2009 conference convened by the National Insti-
tute on Aging and the Alzheimer’s Association, researchers
determined that this discrepancy was mainly a result of two
differences in diagnostic criteria: (1) a diagnosis of dementia
in ADAMS required impairments in daily functioning and
(2) people determined to have vascular dementia in ADAMS
were not also counted as having AD, even if they exhibited
clinical symptoms of Alzheimer’s [86]. Because the more
stringent threshold for dementia in ADAMS may miss peo-
ple with mild AD and because clinical–pathological studies
have shown that mixed dementia resulting from both AD and
vascular pathology in the brain is very common [5], the Alz-
heimer’s Association believes that the larger CHAP esti-
mates may be a more relevant estimate of the burden of
AD in the United States.
A5Numberof women and men age 65 and older with AD in
the United States: The estimates for the number of U.S.
women (3.2 million) and men (1.8 million) age 65 years
and older with AD in 2013 is from unpublished data from
the Chicago Health and Aging Project. For a description of
the analytical methods, see [83].
A6Number of seconds for the development of a new case of
AD: Although AD does not present suddenly like stroke or
heart attack, the rate at which new cases occur can be com-
puted in a similar way. The 68 seconds number is calculated
by dividing the number of seconds in a year (31,536,000) by
the number of new cases in a year. One study estimated that
there would be 454,000 new cases in 2010 and 491,000 new
cases in 2020 [103]. The Alzheimer’s Association calculated
that the incidence of new cases in 2012 would be 461,400 by
multiplying the 10-year change from 454,000 to 491,000
(37,000) by 0.2 (for the number of years from 2010 to
2012 divided by the number of years from 2010 to 2020),
adding that result (7,400) to the estimate by Hebert and col-
leagues [103] for 2010 (454,000)5 461,400. The number of
seconds in a year (31,536,000) divided by 461,400 5 68.3
seconds, rounded to 68 seconds. Using the same method of
calculation for 2050, 31,536,000 divided by 959,000 [103]
5 32.8 seconds, rounded to 33 seconds.
A7Criteria for identifying subjects with AD and other de-
mentias in the Framingham Study: Starting in 1975, nearly2800 people from the Framingham Study who were age 65
years and free of dementia were monitored for as long as
29 years. Standard diagnostic criteria (Diagnostic and Sta-
tistical Manual of Mental Disorders, fourth edition, criteria)
were used to diagnose dementia in the Framingham Study;
but, in addition, the subjects had to have at least “moderate”
dementia according to the Framingham Study criteria, which
is equivalent to a score of 1 point or more on the Clinical De-
mentia Rating scale, and they had to have symptoms for 6
months or more. Standard diagnostic criteria (the National
Institute of Neurological and Communicable Disease and
Stroke–Alzheimer’s Disease and Related Disorders Associ-
ation criteria from 1984) were used to diagnose AD. The ex-
amination for dementia and AD is described in detail
elsewhere [88].
A8Number of baby boomers who will develop AD and
other dementias: The numbers for remaining lifetime risk
of AD and other dementias for baby boomers were devel-
oped by the Alzheimer’s Association by applying the data
provided to the Association on remaining lifetime risk by
Dr. Alexa Beiser, Dr. Sudha Seshadri, Dr. Rhoda Au, and
Dr. Philip A. Wolf from the Departments of Neurology
and Biostatistics, Boston University Schools of Medicine
and Public Health, to U.S. Census data.
A9State-by-state prevalence of AD: These state-by-state
prevalence numbers are based on incidence data from the
Chicago Health and Aging Project (CHAP), projected to
each state’s population, with adjustments for state-specific
gender, years of education, race and mortality [106]. The
numbers in Table 2 are found in online material related to
this article, available at http://www.neurology.org/content/
62/9/1645.extract. These numbers do not add up exactly to
the reported estimate of the total number of Americans
with AD diseaseA1 because they come from slightly different
data sources; the state-by-state data uses 2000 U.S. Census
data.
A10The projected number of people with AD comes from
the Chicago Health and Aging Project: See [83]. Other pro-
jections are somewhat lower [247] because they relied on
more conservative methods for counting people who cur-
rently have AD.A4 Nonetheless, these estimates are statisti-
cally consistent with each other, and all projections
suggest substantial growth in the number of people with
AD during the coming decades.
A11Projected number of people age 65 and older with AD
in 2025: The number 7.1 million is based on a linear extrap-
olation from the projections of prevalence of AD for the
years 2020 (5.8 million) and 2030 (8.4 million) from the
Chicago Health and Aging Project [83].
A12Previous high and low projections of AD prevalence in
2050: The latest projections provided by the U.S. Census do
not include high and low series based on different predic-
tions about future changes to the population. Therefore,
a high and low range for the projection to the year 2050
was not available for the most recent analysis of Chicago
Health and Aging Project data [83]. The previous high and
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icans with AD in 2050 age 65 years and older will range
from 11 million to 16 million [108].
A13Deaths with AD: The estimates for the number of
Americans dying with AD—400,000 in 2010 and 450,000
in 2013—were provided to the Alzheimer’s Association by
Liesi Hebert as unpublished results from her study [83].
A14Number of family and other unpaid caregivers of peo-
ple with AD and other dementias: To calculate this number,
the Alzheimer’s Association started with data from the Be-
havioral Risk Factor Surveillance System (BRFSS). In
2009, the BRFSS survey asked respondents age 18 years
and older whether they had provided any regular care or as-
sistance during the past month to a family member or friend
who had a health problem, long-term illness, or disability.
To determine the number of family members and other un-
paid caregivers nationally and by state, we applied the pro-
portion of national caregivers and for each state from the
2009 BRFSS (as provided by the Centers for Disease Con-
trol and Prevention, Healthy Aging Program, unpubl. data)
to the national number of people age 18 years and older and
in each state from the U.S. Census Bureau report for July
2012. [accessed 2013 Jan 7]. Available at: www.census.
gov/popest/data/datasets.html. To calculate the proportion
of family and other unpaid caregivers who provide care
for a person with AD or other dementias, the Alzheimer’s
Association used data from the results of a national tele-
phone survey conducted in 2009 for the National Alliance
for Caregiving (NAC)/American Association of Retired
Persons (AARP) [224]. The NAC/AARP survey asked re-
spondents age 18 years and older whether they were provid-
ing unpaid care for a relative or friend age 18 years or older
or had provided such care during the past 12 months. Re-
spondents who answered yes were then asked about the
health problems of the person for whom they provided
care. In response, 26% of caregivers said that (1) AD or
other dementia was the main problem of the person for
whom they provided care or (2) the person had AD or other
mental confusion in addition to his or her main problem.
The 26% figure was applied to the total number of care-
givers nationally and in each state, resulting in a total of
15,409,609 AD and other dementias caregivers.
A15Alzheimer’s Association 2010 Women and Alz-
heimer’s Poll: This poll contacted 3118 adults nationwide
by telephone from August 25 to September 3, 2010. Tele-
phone numbers were chosen randomly in separate samples
of landline and cell phone exchanges across the nation, al-
lowing listed and unlisted numbers to be contacted, and
multiple attempts were made to contact each number.
Within households, individuals were selected randomly. In-
terviews were conducted in English and Spanish. The sur-
vey “oversampled” blacks and Hispanics, selected from
U.S. Census tracts with more than 8% concentration of
each group. It also included an oversample of Asians using
a listed sample of Asian households. The combined samples
include 2295 white, non-Hispanic; 326 black; 309 His-panic; 305 Asian; and 135 other race respondents. Cases
were weighted to account for differential probabilities of se-
lection and to account for overlap in the landline and cell
phone sampling frames. The sample was adjusted to match
U.S. Census demographic benchmarks for gender, age, ed-
ucation, race/ethnicity, region, and telephone service. The
resulting interviews comprise a probability-based, national
representative sample of U.S. adults. This national survey
included 202 caregivers of people with AD and other de-
mentias and was supplemented with 300 interviews from
a listed sample of caregivers of people with AD, for a total
of 502 caregiver interviews. A caregiver was defined as an
adult age 18 years or older who, during the past 12 months,
provided unpaid care to a relative or friend age 50 years or
older with AD or other dementias. The weight of the care-
giver sample adjusted all 502 caregiver cases to the
weighted estimates for gender and race/ethnicity derived
from the base survey of caregivers. Questionnaire design
and interviewing were conducted by Abt SRBI of New
York. Susan Pinkus of S.H. Pinkus Research and Associates
coordinated the polling and helped in the analysis of the
poll data.
A16Number of hours of unpaid care: To calculate this
number, the Alzheimer’s Association used data from a fol-
low-up analysis of results from the 2009 National Alliance
for Caregiving (NAC)/American Association of Retired Per-
sons (AARP) national telephone survey (data provided un-
der contract by Matthew Greenwald and Associates,
November 11, 2009). These data show that caregivers of
people with AD and other dementias provided an average
of 21.9 hours/week of care, or 1139 hours/year. The number
of family and other unpaid caregivers (15,409,609)A14 was
multiplied by the average hours of care per year, which totals
17,548,462,657 hours of care.
A17Value of unpaid caregiving: To calculate this number,
the Alzheimer’s Association used the method of Amo and
colleagues [248]. This method uses the average of the fed-
eral minimum hourly wage ($7.25 in 2012) and the mean
hourly wage of home health aides ($17.40 in July 2012)
[249]. The average is $12.33, which was multiplied by the
number of hours of unpaid care (17,548,462,657)A16 to de-
rive the total value of unpaid care ($216,372,544,560).
A18Higher health care costs of AD caregivers: This figure
is based on a methodology originally developed by Dr. Brent
Fulton for The Shriver Report: AWoman’s Nation Takes on
Alzheimer’s [250] A survey of 17,000 employees of a multi-
national firm based in the United States estimated that care-
givers’ health care costs were 8% higher than noncaregivers’
[251]. To determine the dollar amount represented by that
8% figure nationally and in each state, the 8% figure and
the proportion of caregivers from the 2009 Behavioral
Risk Factor Surveillance SystemA14 were used to weight
each state’s caregiver and noncaregiver per capita personal
health care spending in 2009, inflated to 2012 dollars
[252]. The dollar amount difference between the weighted
per-capita personal health care spending of caregivers and
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for caregivers) produced the average additional health care
costs for caregivers in each state. Nationally, this translated
to an average of $592. The amount of the additional cost in
each state, which varied by state from a low of $436 in Utah
to a high of $902 in the District of Columbia, was multiplied
by the total number of unpaid AD and dementia caregivers in
that stateA14 to arrive at that state’s total additional health
care costs of AD and other dementia caregivers as a result
of being a caregiver. The combined total for all states was
$9,121,120,080. Fulton concluded that this is “likely to be
a conservative estimate because caregiving for people with
Alzheimer’s is more stressful than caregiving for most peo-
ple who don’t have the disease” [250].
A19Lewin Model on AD and dementia and costs: These
numbers come from a model created for the Alzheimer’s As-
sociation by The Lewin Group, modified to reflect the more
recent estimates and projections of the prevalence of AD
[83]. The model estimates total payments for community-
based health care services using data from the Medicare
Current Beneficiary Survey (MCBS). The model was con-
structed based on 2004 MCBS data; those data have been
replaced with the more recent 2008 MCBS data.A21 Nursing
facility care costs in the model are based on The Lewin
Group’s Long-Term Care Financing Model. More informa-
tion on the model, its long-term projections, and its method-
ology is available at www.alz.org/trajectory.
A20All cost estimates were inflated to year 2012 dollars
using the Consumer Price Index (CPI): All urban consumers
seasonally adjusted average prices for medical care services.
The relevant item within medical care services was used for
each cost element (e.g., the medical care services item
within the CPI was used to inflate total health care payments,
the hospital services item within the CPI was used to inflate
hospital payments, and the nursing home and adult day ser-
vices item within the CPI was used to inflate nursing home
payments).
A21Medicare Current Beneficiary Survey Report: These
data come from an analysis of findings from the 2008
Medicare Current Beneficiary Survey (MCBS). The analy-sis was conducted for the Alzheimer’s Association by Dr.
Julie Bynum, Dartmouth Institute for Health Policy and
Clinical Care, Center for Health Policy Research. The
MCBS, a continuous survey of a national representative
sample of about 16,000 Medicare beneficiaries, is linked
to Medicare Part B claims. The survey is supported by
the U.S. Centers for Medicare and Medicaid Services.
For community-dwelling survey participants, MCBS inter-
views are conducted in person three times a year with the
Medicare beneficiary or a proxy respondent if the benefi-
ciary is not able to respond. For survey participants who
are living in a nursing home or another residential care fa-
cility, such as an assisted living residence, retirement
home, or a long-term care unit in a hospital or mental
health facility, MCBS interviews are conducted with
a nurse who is familiar with the survey participant and
his or her medical record. Data from the MCBS analysis
that are included in 2013 Alzheimer’s Disease Facts and
Figures pertain only to Medicare beneficiaries age 65
years and older. For this MCBS analysis, people with de-
mentia are defined as follows:
 Community-dwelling survey participants who an-
swered yes to the MCBS question: Has a doctor ever
told you that you had AD or dementia? (proxy re-
sponses to this question were accepted)
 Survey participants who were living in a nursing home
or other residential care facility and had a diagnosis of
AD or dementia in their medical record
 Survey participants who had at least oneMedicare claim
with a diagnostic code for AD or other dementias in
2008; the claim could be for any Medicare service, in-
cludinghospital, skillednursing facility, outpatientmed-
ical care, home health care, hospice or physician, or
other health care provider visit (the diagnostic codes
used to identify survey participants with AD and other
dementias are 331.0, 331.1, 331.11, 331.19, 331.2,
331.7, 331.82, 290.0, 290.1, 290.10, 290.11, 290.12,
290.13, 290.20, 290.21, 290.3, 290.40, 290.41, 290.42,
290.43, 291.2, 294.0, 294.1, 294.10, and 294.11)
